EP0514464A1 - Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell - Google Patents

Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell

Info

Publication number
EP0514464A1
EP0514464A1 EP91904427A EP91904427A EP0514464A1 EP 0514464 A1 EP0514464 A1 EP 0514464A1 EP 91904427 A EP91904427 A EP 91904427A EP 91904427 A EP91904427 A EP 91904427A EP 0514464 A1 EP0514464 A1 EP 0514464A1
Authority
EP
European Patent Office
Prior art keywords
peptide
ala
lys
seq
lle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91904427A
Other languages
German (de)
French (fr)
Other versions
EP0514464A4 (en
Inventor
Barry Berkowitz
W. Lee Maloy
U. Prasad Kari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magainin Pharmaceuticals Inc
Original Assignee
Magainin Sciences Inc
Magainin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Sciences Inc, Magainin Pharmaceuticals Inc filed Critical Magainin Sciences Inc
Publication of EP0514464A1 publication Critical patent/EP0514464A1/en
Publication of EP0514464A4 publication Critical patent/EP0514464A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Thi s invention relates to biologically active peptides , and more particularly to novel biologically active peptides and uses therefor .
  • a biologically active amphiphilic peptide which includes one of the following basic structures X 1 through X 7 wherein :
  • X 2 is -[R 2 -R 2 -R 3 -R 1 -R 2 -R 2 -R 1 ]- n ;
  • X 3 is -[R 2 -R 3 -R 1 -R 2 -R 2 -R 2 -R 2 ]- n ;
  • X 4 is -[R 3- R 1 -R 2 -R 2 -R 1 -R 2 -R 2 ]- n ;
  • X 5 is -[R 1- R 2 -R 2 -R 1 -R 2 -R 2 -R 3 ]- n ;
  • X 6 is -[R 2 -R 2 -R 3 -R 1 -R 2 -R 2 -R 1 ]- n ;
  • X 7 is -[R 2- R 1 -R 2 -R 2 -R 3 -R 1 -R 2 ]- n ;
  • R 1 is a basic hydrophilic amino acid
  • R 2 is a hydrophobic amino acid
  • R 3 is a neutral hydrophilic or hydrophobic amino acid
  • n is from 2 to 5 .
  • the basic hydrophilic amino acids include , but are not limited to Lys , Arg, His , Orn, homoarginine (Har ) , 2 , 4-diamino butyric acid (Dbu ) , and p-aminophenylalanine .
  • the hydrophobic amino acids include, but are not limited to Ala, Cys, Phe, Gly, lie, Leu, Met, Pro, Val, Trp, Tyr, norleucine (Nle), norvaline (Nva), and cyclohexylalanine (Cha).
  • the neutral hydrophilic amino acids include, but are not limited to Asn, Gin, Ser and Thr.
  • the peptide when the peptide includes the structure X 1 , the peptide may include the following
  • the peptide when the peptide includes the structure X 1 , the peptide may include the following structure:
  • the peptide may include the following structure:
  • the peptide may include the following structure:
  • the peptide may include the followin g structure:
  • the peptide may include the following structure:
  • the peptide when the peptide includes the structure X 3 , the peptide may include the following structure:
  • the peptide when the peptide includes the structure X 3 , the peptide may include the following structure :
  • X 3 - Z 3 wherein X 3 is as hereinabove described, and Z 3 is: (i) R 2 ;
  • the peptide may include the following structure:
  • the peptide when the peptide includes the structure X 4 , the peptide may include the following structure:
  • the peptide when the peptide includes the structure X 4 , the peptide may include the following structure:
  • the peptide may include the following structure: (Y 4 ) a - X 4 (Z 4 ) b , wherein X 4 and Z 4 are as previously defined, a is 0 or 1, and b is 0 or 1.
  • the peptide when the peptide includes the structure X 5 , the peptide may include the following structure:
  • the peptide when the peptide includes structure X 5 , the peptide may include the following structure:
  • the peptide may include the following structure:
  • the peptide when the peptide includes the structure X 6 , the peptide may include the following structure:
  • the peptide when the peptide includes the structure X 6 , the peptide may include the following structure:
  • the peptide may include the following structure:
  • the peptide when the peptide includes the structure X 7 , the peptide may include the structure Y 7 -X 7 , wherein X 7 is as hereinabove described, and Y 7 is:
  • the peptide when the peptide includes the structure X 7 , the peptide may include the following structure:
  • the peptide may include the following structure:
  • the peptides and/or analogues or derivatives thereof may be C-terminal acids or amides.
  • n 3
  • the peptide is of one of the following structures listed below and also listed in the accompanying sequence listing:
  • a biologically active amphiphilic peptide which includes the following basic structure X 14 :
  • R 1 , R 2 , and R 3 are as hereinabove described, and R 4 is a basic hydrophilic or hydrophobic amino acid.
  • the peptide may include the following structure:
  • Y 14 -X 14 wherein X 14 is as hereinabove described, and Y 14 is: (i) R 2 ;
  • the peptide may include the following structure:
  • a is 0 or 1
  • b is 0 or 1.
  • the peptide has the following structural formula as indicated in the accompanying sequence listing:
  • the peptide has the amino acid sequence: (a)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl
  • the peptide has one of the following structural formulae as indicated in the
  • n is from 2 to 5.
  • n is 3, and the peptide has the following structural formula:
  • each of the amino acid residues contained in the peptides is a D-amino acid residue or glycine.
  • all of the amino acid residues are either D-amino acid or glycine residues or L-amino acid or glycine residues.
  • amphiphilic peptide is a peptide which includes both hydrophobic and hydrophilic peptide regions.
  • the peptides hereinabove described, and/or analogues or derivatives thereof are generally water soluble to a concentration of at least 20 mg/ml at neutral pH in water.
  • such peptides are non-nemolytic; i.e., they will not rupture blood cells at effective concentrations.
  • the structure of such peptide provides for flexibility of the peptide molecule. When the peptide is placed in water, it does not assume an amphiphilic structure. When the peptide encounters an oily surface or membrane, the peptide chain folds upon itself into a rod-like structure.
  • the peptides and/or analogues or derivatives thereof may be administered to a host; for example a human or non-human animal, in an amount effective to inhibit growth of a target cell, virus, or virally-infected cell.
  • a host for example a human or non-human animal
  • the peptides and/or analogues or derivatives thereof may be used as antimicrobial agents, anti-viral agents, antibiotics, anti-tumor agents, antiparasitic agents, antifungal agents, spermicides, as well as exhibiting other bioactive functions.
  • antimicrobial means that the peptides of the present invention inhibit, prevent, or destroy the growth or proliferation of microbes such as bacteria, fungi, or the like.
  • antibiotic means that the peptides employed in the present invention produce effects adverse to the normal biological functions of the non-host cell, tissue or organism, including death or destruction and prevention of the growth or proliferation of the non-host cell, tissue, or
  • spermicidal as used herein means that the peptides employed in the present invention, inhibit, prevent, or destroy the motility of sperm.
  • antiviral means that the peptides employed in the present invention inhibit, prevent, or destroy the growth or proliferation of viruses, or of virally-infected cells.
  • anti-tumor means that the peptide inhibits the growth of or destroys tumors.
  • antifungal means that the peptides of the present invention may be used to inhibit the growth of or destroy fungi.
  • antiparasitic means that the peptides of the present invention may be used to inhibit the growth of or destroy parasites.
  • the peptides may be administered in vivo or in vitro.
  • the peptides also may be administered directly to a target cell, virus, or virally-ihfected cell, or the peptides may be
  • the peptides of the present invention have a broad range of potent antibiotic activity against a plurality of microorganisms including Gram-positive and Gram-negative bacteria, fungi, protozoa, and the like, as well as parasites.
  • the peptides of the present invention allow a method for treating or controlling microbial infection caused by organisms which are sensitive to the peptides. Such treatment may comprise administering to a host organism or tissue susceptible to or affiliated with a microbial infection an antimicrobial amount of at least one of the peptides.
  • antibiotics because of the antibiotic, antimicrobial, and antiviral properties of the peptides, they may also be used as preservatives or sterilants of materials susceptible to microbial or viral contamination.
  • the peptide and/or derivatives or analogues thereof may be administered in combination with a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
  • a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
  • Such pharmaceutical compositions may be used topically or systemically and may be in any suitable form such as a liquid, solid, semi-solid, injectable solution, tablet, ointment, lotion, paste, capsule, or the like.
  • the peptide compositions may also be used in combination with
  • the peptide(s) of the present invention may be administered to a host; in particular an animal, in an effective antibiotic and/or anti-tumor and/or anti-viral and/or anti-microbial and/or anti-parasitic and/or an ahtispermicidal amount.
  • composition in accordance with the invention will contain an effective anti-microbial amount and/or an effective antispermicidal amount and/or an effective
  • the peptide of the present invention may also be employed in promoting or stimulating healing of a wound in a host.
  • wound healing includes various aspects of the would healing process.
  • peptides increase wound breaking strength.
  • the peptides of the present invention may also be employed so as to reverse the inhibition of wound healing caused by steroids such as cortisone or by conditions which compromise or depress the immune system.
  • the peptides of the present invention may be used in the treatment of external burns and to treat and/or prevent skin and burn infections.
  • the peptides may be used to treat skin and burn infections caused by organisms such as, but not limited to, P. aeruqinosa and S. aureus.
  • the peptides are also useful in the prevention or treatment of eye infections.
  • infections may be caused by bacteria such as, but not limited to, P. aeruqinosa, S. aureus, and N. gonorrhoeae, by fungi such as but not limited to C. albicans and A. fumiqatus, by parasites such as but not limited to A.
  • the peptides may also be effective in killing cysts, spores, or trophozoites of infection - causing organisms.
  • Such organisms include, but are not limited to Acanthamoeba which forms
  • trophozoites or cysts C. albicans, which forms spores, and A. fumiqatus, which forms spores as well.
  • the peptides may also be administered to plants in an effective antimicrobial or antiviral or antiparasitic amount to prevent or treat microbial or viral or parasitic contamination thereof.
  • the peptide is employed to provide peptide dosages of from 0.1 mg. to 500 mg. per kilogram of host weight, when administered systemically. When administered topically, the peptide is used in a concentration of from .05% to 10%.
  • the peptides may be produced by known techniques and
  • the peptides may be synthesized on an automatic peptide synthesizer. Journal of the American Chemical Society, Vol. 85, pgs. 2149-54 (1963). It is also possible to produce such peptides by genetic
  • the peptides of the present invention may be employed in combination with a toxic ion for the purposes hereinabove described.
  • a toxic ion is one which when introduced into a target cell virus, or virally-infected call, inhibits and/or prevents and/or destroys the growth of the target cell, virus, or
  • Such a toxic ion is one which in the absence of an ion channel forming peptide is unable to cross a natural or synthetic lipid membrane; in particular a cell membrane, in sufficient amounts to affect a cell adversely.
  • the peptide and toxic ion may be administered as a single composition or in separate compositions, and the single or separate compositions may include additional materials, actives and/or inactives, in addition to the peptide and toxic ion.
  • toxic ions there may be mentioned fluoride, peroxide, bicarbonate, and silver ions.
  • the peptide and the toxic ion are employed in amounts effective to inhibit and/or prevent and/or destroy the growth of the target cell, virus, or virally-infected cell.
  • the ion potentiates the action of the peptide, i.e., the amount of toxic ion is effective to reduce the minimum effective concentration of the peptide for inhibiting growth of a target cell, virus, or virally-infected cell.
  • the toxic ion when used topically, is generally employed in a concentration of from 0.05% to 2.0%. When used systemically, the ion is generally employed in an amount of from 1 to 10 mg. per kg. of host weight. Peptide dosages may be within the ranges hereinabove described.
  • the peptide and toxic ion may be delivered or administered in different forms; for example, the toxic ion may be administered orally, while the peptide may be administered by IV or IP.
  • the peptide could be administered in an amount of up to about 1% weight to weight and the toxic ion delivered in an amount of about 50mM (about 0.1%).
  • the toxic ion in the form of a salt such as sodium fluoride, could be administered orally in conjunction with systemic administration of the peptide.
  • the peptide may be administered IV or IP to achieve a serum dose of 100 micrograms per milliliter (10 milligrams per kilogram) in conjunction with an oral dose of toxic ion, in particular, sodium fluoride, of 10 meq per kilogram.
  • the peptides of the present invention may be administered to a host in combination with an antibiotic selected from the class consisting of
  • bacitracins gramacidin, polymyxin, vancomycin, teichoplanin, aminoglycosides, hydrophobic antibiotics, penicillins,
  • the bacitracins gramacidin, polymyxin, vancomycin,
  • teichoplanin and derivatives and analogues thereof, are a group of polypeptide antibiotics.
  • a preferred bacitracin is bacitracin A.
  • Aminoglycosid ⁇ antibiotics include tobramycin, kanamycin, amikacin, the gentamicins (e.g., gentamicin C 1 , gentamicin C 2 , gentamicin C 1a ), n ⁇ tilmicin, kanamycin, and derivatives and analogues thereof.
  • the preferred aminoglycosides are tobramycin and the gentamicins.
  • the aminoglycosides, and the bacitracins hereinabove described, tend to be hydrophilic and water-soluble.
  • Penicillins which may be employed include, but are not limited to benzyl penicillin, ampicillin, methicillin
  • dicloxacillin dicloxacillin, .flucloxacillin, amoxicillin, and amidinocillin.
  • Preferred penicillins which may be employed are benzyl penicillin and ampicillin.
  • a preferred monobactam which may be employed is aztreonam.
  • hydrophobic antibiotics which may be used in the present invention, there may be mentioned macrolides such as erythromycin, roxythromycin, clarithromycm, etc.; 9-N-alkyl derivatives of erythromycin; midecamycin acetate; azithromycin; flurithromycin; rifabutin; rokitamycin, a
  • CGP-279353 (Ciba-Geigy); an erythromycin A derivative with a cyclic carbamate fused to the C 11 /C 12 position of a macrolide ring known as A-62514 (Abbott); AC-7230 (Toyo Jozo);
  • rifamycin carbenicillin, and nafcillin may be employed as well.
  • antibiotics which are 50-S ribosome inhibitors such as lincomycin; clindamycin; and chloramphenicol; etc.;
  • antibiotics which have a large lipid like lactone ring, such as mystatin; pimaricin, etc.
  • the peptide and antibiotic may be adminstered by direct administration to a target ceil or by systemic or topical administration to a host which includes the target cell, in order to prevent, destroy or inhibit the growth of a target cell.
  • Target cells whose growth may be prevented, inhibited, or destroyed by the administration of the peptides and antibiotic include Gram-positive and Gram-negative bacteria as well as fungal cells.
  • the antibiotic such as those hereinabove described, or derivatives or analogues thereof, when used topically, is generally employed in a concetration of about 0.1% to about 10%.
  • the antibiotic or derivative or analogue thereof when used systemically, is generally employed in an amount of from 1.25 mg. to about 45 mg. per kg. of host weight per day.
  • Peptide dosages may be those as hereinabove described.
  • the peptide could be admnistered in an amount of from about 0.1% to about 10% weight to weight, and the antibiotic is delivered in an amount of from about 0.1% to about 10% weight to weight.
  • the peptides of the present invention may be administered in combination with an antiparasitic agent or an antifungal agent.
  • Antiparasitic agents which may be employed include, but are not limited to, anti-protozoan agents.
  • specific anti-parasitic agents which may be employed include, but are not limited to, pentamidine isethionate, and propamidine isethionate (Brolene).
  • Anti-fungal agents which may be employed include, but are not limited to, ketoconazole. It is also to be understood that certain anti-parasitic agents may also have anti-fungal activity, and that certain anti-fungal agents may have anti-parasitic activity.
  • the peptides of the present invention may be administered in combination with an antibiotic which inhibits DNA gyrase, which is an enzyme involved in the formation of bonds between individual coiling strands of replicating bacterial DNA.
  • DNA gyrase is necessary for the normal replication- of bacterial DNA, and, therefore, antibiotics which inhibit DNA gyrase inhibit the normal replication of bacterial DNA.
  • antibiotics which inhibit DNA gyrase include nalidixic acid, oxolinic acid, cinoxacin, and quinolone
  • antibiotics which include ciprofloxacin, norfloxacin, ofloxacin, enoxacin, pefloxacin, lomefloxacin, fleroxacin, tosulfloxacin, temafloxacin, and rufloxacin.
  • the peptides of the present invention may be administered for the purpose hereinabove described in combination with other biologically active
  • amphiphilic peptides or in combination with ion channel-forming proteins.
  • biologically active amphiphilic peptides which may be employed in combination with the peptides of the present invention include magainin peptides, PGLa peptides, XPF peptides, CPF peptides, cecropins and sarcotoxins.
  • a magainin peptide is either a magainin such as magainin I, II, or III or an analogue or derivative thereof.
  • the magainin peptides generally include at least fourteen amino acids.
  • a magainin peptide preferably has 22 or 23 amino acids.
  • Magainin peptides are described in Proc. Natl. Acad. Sci., Vol. 84, pgs. 5449-53 (Aug. 87).
  • magainin peptides refers to the magainin peptides as well as
  • derivatives and analogues thereof including but not limited to the representative derivatives and analogues.
  • a PGLa peptide is either PGLa or an analogue or derivative thereof.
  • the PGLa peptides generally include at least seventeen amino acids and may include as many as forty amino acids.
  • An XPF peptide is either XPF or an analogue or derivative thereof.
  • the XPF peptides generally include at least nineteen amino acids and may include up to forty amino acids.
  • PGLa and XPF peptides there may be mentioned the following peptide sequences as well as appropriate analogues and derivatives thereof:
  • a CPF peptide is either a CPF peptide or an analogue or derivative thereof. In general, a CPF peptide does not include more than 40 amino acids.
  • cecropins includes the basic structure as well as analogues and derivatives thereof.
  • cecropins and analogues and derivatives thereof are described in Ann. Rev. Microbiol. 1987, Vol. 41, pages 103-26, in particular page 108, and in
  • sarcotoxins includes the basic materials as well as analogues and derivatives thereof.
  • the sarcotoxins and analogues and derivatives thereof are described in Molecular Entomology, pages 369-78, in particular page 375, Alan R. liss, Inc. (1987), which is hereby incorporated by reference.
  • Ion channel-forming proteins or peptides which may be employed in combination with the peptides of the present
  • defensins also known as human neutrophil antimicrobial peptides (HNP), major basic protein (MBP) of eosinophils, bactericidal permeability-increasing protein (BPI), and a pore-forming cytotoxin called variously perforin,
  • cytolysin or pore-forming protein.
  • Deferisins are described in Selsted, et al., J. Clin. Invest., Vol. 76, pgs. 1436-1439
  • MBP proteins are described in Wasmoen, et al., J. Biol. Chem., Vol. 263, pgs 12559-12563. (1988).
  • BPI proteins are described in Ooi, et al, J. Biol. Chem., Vol. 262, pgs.
  • ion channel-forming proteins includes the basic structures of the ion-forming proteins as well as analogues and derivatives.
  • Stock solutions of the following Peptides (SEQ ID NO: 1) through (SEQ ID NO: 64) in accordance with the present invention are prepared at a concentration of 512 ⁇ g/ml in sterile deionized distilled water and stored at -70°C.
  • Peptide (1A) is of the same structural formula as Peptide (SEQ ID NO: 1), except that each amino acid residue is a D-amino acid residue.
  • the stock peptide solution is diluted in serial dilutions (1:2) down the wells of a microtiter plate so that the final concentrations of peptides in the wells are 0.25, 0.50, 1, 2, 4, 8, 16, 32, 64, 128, and 256 ⁇ g/ml.
  • 1-5 X 10 5 CFUs/ml of either S. aureus ATCC 25923, E. coli ATCC 25922, or P. aeruqinosa ATCC 27853 were added to the wells in full strength Mueller Hinton broth (BBL 11443) from a mid-log culture.
  • the inoculum is standarized spectrophotometrically at 600nm and is verified by colony counts.
  • MIC minimal inhibitory concentration
  • S is the MIC of the peptide against S. aureus
  • P is the MIC of the peptide against P. aeruqinosa
  • E is the MIC of the peptide against
  • proteose-peptone 0.5% yeast extract; 0.5% glucose; pH 7.2.
  • Minimum Inhibitory Concentration (MIC) and Minimum Amoebicidal Concentration (MAC) of the trophozoites the contents of appropriate flasks were centrifuged, washed free of "old" medium and peptide with dilute saline, resuspended in fresh ppyg medium, and transferred to Corning tissue culture tubes (16 X 125mm). The tubes were incubated at 30°C and examined at daily intervals for growth of amoebas. Minimum Amoebicidal Concentration is defined is the minimum concentration of peptide necessary to kill the trophozoites. The results are given in Table II below. TABLE II
  • peptides of the present invention whether administered alone or in combination with agents such as toxic ions,
  • antibotics or other biologically active peptides or proteins as hereinabove described, may be employed in a wide variety of pharmaceutical compositions in combination with a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
  • a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution.
  • Such pharmaceutical compositions may be used topically or systemically and may be in any suitable form such as a liquid, solid, semi-solid, injectable solution, tablet, ointment, lotion, paste, capsule or the like.
  • peptide and/or agent as hereinabove described may also be used in combination with adjuvants, protease inhibitors, or compatible drugs where such a combination is seen to be desirable or advantageous in controlling infection caused by harmful microorganisms including protozoa, viruses, parasites, fungi, and the like.
  • the peptide may be administerd to a host in particular an animal, in an effective antibiotic and/or anti-tumor and/or antiviral and/or antimicrobial and/or antispermicidal and/or antifungal and/or antiparasitic amount, or in an amount effective to stimulate wound healing in a host.
  • the peptides may be administerd either alone or in combination with a toxic ion, antibiotic, or ion channel forming peptide or protein as
  • the peptide When the peptide is administered in combination with a toxic ion, the activity of the peptide is potentiated.
  • the peptide When the peptide is administered in combination with an agent as hereinabove described, it is possible to administer the peptide and agent in separate forms.
  • the agent may be administered systemically and the peptide may be administered topically.
  • the peptide When the peptide is adminitered topically, it may be administered in combination with a water-soluble vehicle, said water-soluble vehicle being in the form of an ointment, cream, lotion, paste or the like.
  • water-soluble vehicles which may be employed include, but are not limited to, glycols, such as polyethylene glycol, hydroxycellulose, and KY Jelly.
  • the water-soluble vehicle is preferably free of an oily substance.
  • the peptide may also be employed in combination with a toxic ion as hereinabove described in the form of an oral composition for oral hygiene.
  • a composition may be incorporated into a wide variety of compositions and materials used for oral hygiene purposes, which include, but are not limited to, toothpastes, mouthwashes, tooth gels, and tooth powders.
  • Such composition may thus be used to treat or prevent periodontal disease, to prevent or reduce plaque, and/or to prevent or treat or reduce dental caries.
  • the peptide and toxic ion may be used to inhibit, prevent, or destroy the growth of Streptococcus mutans, which is associated with dental caries and periodontal disease.
  • ADDRESSEE Carella, Byrne, Bain, Gilfillan,

Abstract

Est décrit un peptide amphiphile biologiquement actif qui, selon l'aspect de la présente invention, comporte une des structures de base suivante X1 à X7, où: X1 est [R1-R2-R2-R3-R1-R2-R2]-n; X2 est -[R2-R2-R3-R1-R2-R2-R1]-n; X3 est -[R2-R3-R1-R2-R2-R1-R2]-n; X4 est -[R3-R1-R2-R2-R1-R2-R2]-n; X5 est -[R1-R2-R2-R1-R2-R2-R3]-n; X6 est -[R2-R2-R1-R2-R2-R3-R1]-n; et X7 est -[R2-R1-R2-R2-R3-R1-R2]-n; où R1 est un aminoacide hydrophile basique, R2 est un aminoacide hydrophobe, R3 est un aminoacide hydrophile neutre, hydrophile basique ou hydrophobe et n vaut de 2 à 5. Ces compositions peptidiques s'utilisent pour inhiber la croissance d'une cellule cible, d'un virus ou d'une cellule contaminée par virus.A biologically active amphiphilic peptide is described which, according to the aspect of the present invention, comprises one of the following basic structures X1 to X7, where: X1 is [R1-R2-R2-R3-R1-R2-R2] -n ; X2 is - [R2-R2-R3-R1-R2-R2-R1] -n; X3 is - [R2-R3-R1-R2-R2-R1-R2] -n; X4 is - [R3-R1-R2-R2-R1-R2-R2] -n; X5 is - [R1-R2-R2-R1-R2-R2-R3] -n; X6 is - [R2-R2-R1-R2-R2-R3-R1] -n; and X7 is - [R2-R1-R2-R2-R3-R1-R2] -n; where R1 is a basic hydrophilic amino acid, R2 is a hydrophobic amino acid, R3 is a neutral hydrophilic, basic hydrophilic amino acid or hydrophobic and n is from 2 to 5. These peptide compositions are used to inhibit the growth of a target cell, d 'a virus or virus-contaminated cell.

Description

BIOLOGICALLY ACTIVE AMPHIPHILIC PEPTIDES AND METHOD OF INHIBITING GROWTH OF TARGET CELLS , VIRUS OR VIRALLY-INFECTED CELL
This application is a continuation-in-part of application Serial No . 476 , 629 , filed February 8 , 1990.
Thi s invention relates to biologically active peptides , and more particularly to novel biologically active peptides and uses therefor .
In accordance with an aspect of the present invention, there is provided a biologically active amphiphilic peptide which includes one of the following basic structures X1 through X7 wherein :
X1 i s -[R1-R2-R2-R3-R1-R2-R2]-n;
X2 is -[R2-R2-R3-R1-R2-R2-R1]-n;
X3 is -[R2-R3-R1-R2-R2-R2-R2]-n;
X4 is -[R3-R1-R2-R2-R1-R2-R2]-n;
X5 is -[R1-R2-R2-R1-R2-R2-R3]-n;
X6 is -[R2-R2-R3-R1-R2-R2-R1]-n; and
X7 is -[R2-R1-R2-R2-R3-R1-R2]-n;
wherein R1 is a basic hydrophilic amino acid, R2 is a hydrophobic amino acid, R3 is a neutral hydrophilic or hydrophobic amino acid, and n is from 2 to 5 .
The basic hydrophilic amino acids include , but are not limited to Lys , Arg, His , Orn, homoarginine (Har ) , 2 , 4-diamino butyric acid (Dbu ) , and p-aminophenylalanine . The hydrophobic amino acids include, but are not limited to Ala, Cys, Phe, Gly, lie, Leu, Met, Pro, Val, Trp, Tyr, norleucine (Nle), norvaline (Nva), and cyclohexylalanine (Cha).
The neutral hydrophilic amino acids include, but are not limited to Asn, Gin, Ser and Thr.
In accordance with one embodiment, when the peptide includes the structure X1, the peptide may include the following
structure:
Y1-X1, wherein X1 is as hereinabove described, and Y is: (i) R2'
(ii) R2-R2;
(iii) R1-R2-R2;
(iv) R3-R1-R2-R2;
(v) R2-R3-R1-R2-R2; or
(vi) R2-R2-R3-R1-R2-R2, wherein R1, R2, and R3 are as hereinabove described
In accordance with another embodiment, when the peptide includes the structure X1, the peptide may include the following structure:
X1-Z1, wherein X1 is as hereinabove described, and Z1 is:
(i) R1;
(ii) R1-R2;
(iii) R1-R2-R2;
(iv) R1-R2-R2-R3;
(v) R1-R2-R2-R3-R1; or
(vi) R1-R2-R2-R3-R1-R2.
In accordance with yet another embodiment, the peptide may include the following structure:
(Y1)a-X1-(Z1)b, wherein Y1 and Z1 are as previously defined, a is 0 or 1, and b is 0 or 1.
When the peptide includes the structure X2, the peptide may include the following structure:
Y2 - X2, wherein X2 is as hereinabove described, and Y2 is: ( i ) R1 ;
( ii ) R2-R1 ;
( iii ) R2-R2-R1 ;
( iv ) R1-R2-R2-R1 ;
(v ) R3-R1-R2-R2-R1 ; or
( vi ) R2-R3-R1 -R2-R2-R1 .
In another embodiment, the peptide may include the following structure:
X2 - Z2 wherein X2 is as hereinabove described, and Z9 is: (i) R2;
(ii) R2-R2;
(iii) R2-R2-R3;
(iv) R2-R2-R3-R1;
(V) R2-R2-R3-R1-R2; or
(Vi) R2-R2-R3-R1-R2-R2.
In accordance with yet another embodiment, the peptide may include the following structure:
(Y2)a - X2 - (Z2)b, wherein Y2 and Z2 are as previously defined, a is 0 or 1, and b is 0 or 1.
In accordance with another embodiment, when the peptide includes the structure X3, the peptide may include the following structure:
Y3 - X3 wherein X3 is as hereinabove described, and Y3 is:
(i) R2;
(ii) R1-R2,
(iii) R2-R1-R2;
(iv) R2-R2-R1-R2;
(v) R1-R2-R2-R1-R2; or
(vi) R3-R1-R2-R2-R1-R2, wherein R1, R2, and R3 are as hereinabove described.
In accordance with another embodiment, when the peptide includes the structure X3, the peptide may include the following structure :
X3 - Z3 wherein X3 is as hereinabove described, and Z3 is: (i) R2;
(ii) R2-R3;
(iii) R2-R3-R1;
(iv) R2-R3-R1-R2;
(v) R2-R3-R1-R2-R2; or
(vi) R2-R3-R1-R2-R2-R1.
In accordance with yet another embodiment, the peptide may include the following structure:
(Y3)a - X3 - (23)b, wherein Y and Z are as previously defined, a is 0 or 1, and b is 0 or 1.
In accordance with yet another embodiment, when the peptide includes the structure X4, the peptide may include the following structure:
Y4 - X4, wherein X4 is as hereinabove described, and Y4 is:
(i) R2;
(ii) R2-R2;
(iii) R1-R2-R2;
(iv) R2-R1-R2-R2;
(v) R2-R2-R1-R2-R2; or
(vi) R1-R2-R2-R1-R2-R2, wherein R1, R2 and R3 are as hereinabove described.
In accordance with another embodiment, when the peptide includes the structure X4, the peptide may include the following structure:
X4-Z4, wherein X4 is as hereinabove described, and Z4 is:
(i) R3;
(ii) R3-R1;
(iii) R3-R1-R2;
(iv) R3-R1-R2 R2;
(v) R3-R1-R2-R2-R1; or
(vi) R3-R1-R2-R2-R1-R2.
In accordance with yet another embodiment, the peptide may include the following structure: (Y4)a- X4 (Z4)b, wherein X4 and Z4 are as previously defined, a is 0 or 1, and b is 0 or 1.
In accordance with a further embodiment, when the peptide includes the structure X5, the peptide may include the following structure:
Y5-X5, wherein X5 is as hereinabove described, and Y5 is:
(i) R3;
(ii) R2-R3;
(iii) R2-R2-R3;
(iv) R1-R2-R2-R3;
(V) R2-R1-R2-R2-R3; or
(vi) R2-R2-R1-R2-R2-R3, wherein R1, R2, and R3 are as hereinabove described.
In accordance with another embodiment, when the peptide includes structure X5, the peptide may include the following structure:
X5 - Z5 wherein X5 is as hereinabove described, and Z5 is: (i) R1;
(ii) R1-R2;
(iii) R1-R2-R2;
(iv) R1-R2-R2-R1;
(V) R1-R2-R2-R1-R2; or
(Vi) R1-R2-R2-R1-R2-R2.
In accordance with yet another embodiment, the peptide may include the following structure:
(Y5)a- X5 (Z5)b, wherein X5 and Z5 are as previously defined, a is 0 or 1, and b is 0 or 1.
In accordance with a further embodiment, when the peptide includes the structure X6, the peptide may include the following structure:
Y6 - X6 wherein X6 is as hereinabove described, and Y6 is:
(i) R1;
(ii) R3-R1;
(iii) R2-R3-R1; ( iv) R2-R2-R3-R1 ;
(V) R1-R2-R2-R3-R1 ; or
(vi) R2-R1-R2-R2-R3-R1, wherein R1, R2, and R3 are as hereinabove described.
In accordance with another embodiment, when the peptide includes the structure X6, the peptide may include the following structure:
X6-Z6, wherein X6 is as hereinabove described, and Z6 is:
(i) R2;
(ii) R2-R2;
(iii) R2-R2-R1;
(iv) R2-R2-R1-R2;
(V) R2-R2-R1-R2-R2; or
(Vi) R2-R2-R1-R2-R2-R3.
In accordance with yet another embodiment, the peptide may include the following structure:
(Y6)a- X6 (Z6)b, wherein Y6 and Z6 are as previously defined, a is 0 or 1, and b is 0 or 1.
In accordance with one embodiment, when the peptide includes the structure X7, the peptide may include the structure Y7-X7, wherein X7 is as hereinabove described, and Y7 is:
(i) R2;
(ii) R1-R2;
(iii) R3-R1-R2;
(iv) R2-R3-R1-R2;
(v) R2-R2-R3-R1-R2; or
(vi) R1-R2-R2-R3-R1-R2, wherein R1, R2, and R3 are as hereinabove described.
In accordance with a further embodiment, when the peptide includes the structure X7, the peptide may include the following structure:
X7 - Z7 wherein X7 is as hereinabove described, and Z7 is:
(i) R2;
(ii) R2-R1; (iii) R2-R1-R2
(iv) R2-R1-R2-R2;
(v) R2-R1-R2-R2-R3; or
(vi) R2-R1-R2-R2-R3-R1.
In accordance with yet another embodiment, the peptide may include the following structure:
(Y7)a- X7 (Z7)b, wherein Y7 and Z7 are as previously defined, a is 0 or 1, and b is 0 or 1.
The peptides and/or analogues or derivatives thereof, may be C-terminal acids or amides.
In a preferred embodiment, n is 3, and most preferably the peptide is of one of the following structures listed below and also listed in the accompanying sequence listing:
(Lys lie Ala Gly Lys lie Ala )3-NH2 (SEQ ID NO: 1)
(Lys lie Ala Lys lie Ala Gly )3-NH2 (SEQ ID NO: 2 )
(Lys lle Ala Gly Lys lie Gly )3-NH2 (SEQ ID NO: 3)
(Lys Leu Ala Gly Lys Leu Ala )3-NH2 (SEQ ID NO: 4)
( Lys Phe Ala Gly Lys Phe Ala )3-NH2 ( SEQ ID NO : 5 )
(Lys Ala Leu Ser Lys Ala Leu )3-NH2 (SEQ ID NO: 6)
(Lys Leu Leu Lys Ala Leu Gly )3-NH2 (SEQ ID NO: 7)
( Lys Ala He Gly Lys Ala Ile )3-NH2 ( SEQ ID NO : 8 )
(Gly lle Ala Lys lle Ala Lys )3-NH2 (SEQ ID NO: 9)
(Lys lle Ala Lys lle Phe Gly )3-NH2 (SEQ ID NO: 10)
(Gly lle Ala Arg lle Ala Lys )3-NH2 (SEQ ID NO: 11)
(Lys Phe Ala Arg lle Ala Gly )3-NH2 (SEQ ID NO: 12)
(Gly Phe Ala Lys lle Ala Lys)3-NH2 (SEQ ID NO: 13)
(Lys lle Ala Gly Orn lle Ala )3-NH2 (SEQ ID NO: 14)
(Lys lle Ala Arg lle Ala Gly )3-NH2 (SEQ ID NO: 15)
(Orn lle Ala Gly Lys lle Ala)3-NH2 (SEQ ID NO: 16)
(Gly lle Ala Arg lle Phe Lys)3-NH2 (SEQ ID NO: 17)
(Lys Nle Ala Gly Lys Nle Ala )3-NH2 (SEQ ID NO: 18)
(Lys Nle Ala Gly Lys lle Ala )3-NH2 (SEQ ID NO: 19)
(Lys lle Ala Gly Lys Nle Ala )3-NH2 (SEQ ID NO: 20)
(Lys Nva Ala Gly Lys Nva Ala )3-NH2 (SEQ ID NO: 21) (Lys Nva Ala Gly Lys lle Ala)3-NH2 (SEQ ID NO: 22)
(Lys Leu Leu Ser Lys Leu Gly )3-NH2 (SEQ ID NO: 23)
(Lys Leu Leu Ser Lys Phe Gly )3-NH2 (SEQ ID NO: 24)
(Lys lle Ala Gly Lys Nva Ala )3-NH2 (SEQ ID NO: 25)
(His lle Ala Gly His lle Ala )3-NH2 (SEQ ID NO: 26)
(Ala Gly Lys lle Ala Lys lle )3-NH2 (SEQ ID NO: 27)
(lle Ala Lys lle Ala Gly Lys)3-NH2 (SEQ ID NO: 28)
(Lys lle Ala Gly Arg lle Ala )3-NH2 (SEQ ID NO: 29)
(Arg lle Ala Gly Arg lle Ala )3-NH2 (SEQ ID NO: 30)
(Lys Val Ala Gly Lys lle Ala )3-NH2 (SEQ ID NO: 31)
(Lys lle Ala Gly Lys Val Ala )3-NH2 (SEQ ID NO: 32)
(Ala Lys lle Ala Gly Lys lle )3-NH2 (SEQ ID NO: 33)
(Orn lle Ala Gly Orn lle Ala )3-NH2 (SEQ ID NO: 34)
(Lys Phe Ala Gly Lys lle Ala )3-NH2 (SEQ ID NO: 35)
(Lys lle Ala Gly Lys Phe Ala )3-NH2 (SEQ ID NO: 36)
(Lys Cha Ala Gly Lys Ile Ala )3-NH2 (SEQ ID NO: 37)
(Lys Nle Ala Lys Ile Ala Gly )3-NH2 (SEQ ID NO: 38)
(Arg lle Ala Gly Lys lle Ala)3-NHH2 (SEQ ID NO: 39)
(Har lle Ala Gly Har lle Ala )3-NH2 (SEQ ID NO: 40)
(Xaa lle Ala Gly Lys lle Ala )3-NH2 (SEQ ID NO: 41)
(Lys lle Ala Gly Xaa lle Ala )3-NH2 (SEQ ID NO: 42)
In (SEQ ID NO:41) and (SEQ ID NO:42), Xaa is
p-aminophenylalanine.
In accordance with another aspect of the present invention, there is provided a biologically active amphiphilic peptide which includes the following basic structure X14:
R1-R2-R2-R3-R4-R2-R2-R1-R2-R2-R2-R4-R2-R2,
wherein R1, R2, and R3 are as hereinabove described, and R4 is a basic hydrophilic or hydrophobic amino acid.
In accordance with one embodiment, the peptide may include the following structure:
Y14-X14, wherein X14 is as hereinabove described, and Y14 is: (i) R2;
(ii) R2-R2;
(iii) R4-R2-R2;
(iv) R3-R4-R2-R2;
(v) R2-R3-R4-R2-R2;
(vi) R2-R2-R3-R4-R2-R2, or
(vii) R1-R2-R2-R3-R4-R2-R2,wherein R1, R2, R3 and R4 are as hereinabove described.
In accordance with another embodiment, the peptide may include the following structure:
X14-Z14, wherein X 14 is as hereinabove described and Z14 is:
(i) R1;
(ii) R1-R2;
(iii) R1-R2-R2;
(iv) R1-R2-R2-R3;
(V) R1-R2-R2-R3-R4;
(vi) R1-R2-R2-R3-R4-R2; or
(vii) R1-R2-R2-R3-R4-R2-R2, wherein R1, R2, R3, and R4 are as hereinabove described.
In accordance with yet another embodiment the peptide may include the following structure:
(Y14)a-X14-(Z14)b, wherein X and Y are as previously
defined, a is 0 or 1, and b is 0 or 1. In a preferred
embodiment, the peptide has the following structural formula as indicated in the accompanying sequence listing:
(SEQ ID NO: 43)-NH2.
In another preferred embodiment, the peptide has the
following structural formula as indicated in the accompanying sequence listing:
(SEQ ID NO: 44)-NH2.
In accordance with a further embodiment, the peptide has one of the following structural formulae as indicated in the
accompanying sequence listing:
(SEQ ID NO: 45)-NH2 (SEQ ID NO: 46)-NH2
(SEQ ID NO: 47)-NH2
(SEQ ID NO: 48)-NH2
(SEQ ID NO: 49)-NH2
(SEQ ID NO: 50)-NH2
(SEQ ID NO: 51)-NH2
(SEQ ID NO: 52)-NH2
(SEQ ID NO: 53)-NH2
(SEQ ID NO: 54)-NH2
(SEQ ID NO: 55)-NH2
(SEQ ID NO: 56)-NH2
(SEQ ID NO: 57)-NH2
(SEQ ID NO: 58)-NH2
(SEQ ID NO: 59)-NH2
In accordance with another aspect of the present invention, there is provided a biologically active amphiphilic peptide which includes the following structural formula:
-(Lys lle Ala Lys Lys lle Ala)- wherein n is from 2 to 5. Preferably, n is 3, and the peptide has the following structural formula:
(Lys lle Ala Lys Lys lle Ala)3-NH2. (SEQ ID NO: 60).
In accordance with another aspect of the present invention, there is provided a biologically active amphiphilic peptide selected from the group consisting of the following structural formulae as given in the accompanying sequence listing:
(SEQ ID NO: 61)-NH2
(SEQ ID NO: 62)-NH2
(SEQ ID NO: 63)-NH2
(SEQ ID NO: 64)-NH2
In accordance with one embodiment, each of the amino acid residues contained in the peptides is a D-amino acid residue or glycine. Although the scope of this particular embodiment is not to be limited to any theoretical reasoning, it is believed that the above-mentioned peptides, when consisting entirely of D-amino acid or glycine residues, may have increased resistance to proteolytic enzymes while retaining their biological activity. Such peptides thus may be administered orally. Thus in
accordance with a preferred embodiment, all of the amino acid residues are either D-amino acid or glycine residues or L-amino acid or glycine residues.
An amphiphilic peptide is a peptide which includes both hydrophobic and hydrophilic peptide regions.
In general, the peptides hereinabove described, and/or analogues or derivatives thereof are generally water soluble to a concentration of at least 20 mg/ml at neutral pH in water. In addition, such peptides are non-nemolytic; i.e., they will not rupture blood cells at effective concentrations. In addition, the structure of such peptide provides for flexibility of the peptide molecule. When the peptide is placed in water, it does not assume an amphiphilic structure. When the peptide encounters an oily surface or membrane, the peptide chain folds upon itself into a rod-like structure.
The peptides and/or analogues or derivatives thereof may be administered to a host; for example a human or non-human animal, in an amount effective to inhibit growth of a target cell, virus, or virally-infected cell. Thus, for example, the peptides and/or analogues or derivatives thereof may be used as antimicrobial agents, anti-viral agents, antibiotics, anti-tumor agents, antiparasitic agents, antifungal agents, spermicides, as well as exhibiting other bioactive functions.
The term "antimicrobial" as used herein means that the peptides of the present invention inhibit, prevent, or destroy the growth or proliferation of microbes such as bacteria, fungi, or the like.
The term "antibiotic" as used herein means that the peptides employed in the present invention produce effects adverse to the normal biological functions of the non-host cell, tissue or organism, including death or destruction and prevention of the growth or proliferation of the non-host cell, tissue, or
organism, when contacted with the peptides.
The term "spermicidal" as used herein means that the peptides employed in the present invention, inhibit, prevent, or destroy the motility of sperm.
The term "antiviral" as used herein means that the peptides employed in the present invention inhibit, prevent, or destroy the growth or proliferation of viruses, or of virally-infected cells.
The term anti-tumor as used herein means that the peptide inhibits the growth of or destroys tumors.
The term "antifungal" as used herein means that the peptides of the present invention may be used to inhibit the growth of or destroy fungi.
The term "antiparasitic" as used herein means that the peptides of the present invention may be used to inhibit the growth of or destroy parasites.
The peptides may be administered in vivo or in vitro. The peptides also may be administered directly to a target cell, virus, or virally-ihfected cell, or the peptides may be
administered systemically.
The peptides of the present invention have a broad range of potent antibiotic activity against a plurality of microorganisms including Gram-positive and Gram-negative bacteria, fungi, protozoa, and the like, as well as parasites. The peptides of the present invention allow a method for treating or controlling microbial infection caused by organisms which are sensitive to the peptides. Such treatment may comprise administering to a host organism or tissue susceptible to or affiliated with a microbial infection an antimicrobial amount of at least one of the peptides.
Because of the antibiotic, antimicrobial, and antiviral properties of the peptides, they may also be used as preservatives or sterilants of materials susceptible to microbial or viral contamination.
The peptide and/or derivatives or analogues thereof may be administered in combination with a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution. Such pharmaceutical compositions may be used topically or systemically and may be in any suitable form such as a liquid, solid, semi-solid, injectable solution, tablet, ointment, lotion, paste, capsule, or the like. The peptide compositions may also be used in combination with
adjuvants, protease inhibitors, or compatible drugs where such a combination is seen to be desirable or advantageous in
controlling infection caused by harmful microorganisms including protozoa, viruses, and the like, as well as by parasites.
The peptide(s) of the present invention may be administered to a host; in particular an animal, in an effective antibiotic and/or anti-tumor and/or anti-viral and/or anti-microbial and/or anti-parasitic and/or an ahtispermicidal amount.
Depending on the use, a composition in accordance with the invention will contain an effective anti-microbial amount and/or an effective antispermicidal amount and/or an effective
anti-viral amount and/or an effective anti-tumor amount and/or an effective antibiotic amount and/or anti-parasitic amount of one or more of the hereinabove described peptides which have such activity.
The peptide of the present invention may also be employed in promoting or stimulating healing of a wound in a host.
The term "wound healing" as used herein includes various aspects of the would healing process.
These aspects include, but are not limited to, increased contraction of the wound, increased deposition of connective tissue, as evidenced by, for example, increased deposition of collagen in the wound, and increased tensile strength of the wound, i.e., the peptides increase wound breaking strength. The peptides of the present invention may also be employed so as to reverse the inhibition of wound healing caused by steroids such as cortisone or by conditions which compromise or depress the immune system.
The peptides of the present invention may be used in the treatment of external burns and to treat and/or prevent skin and burn infections. In particular, the peptides may be used to treat skin and burn infections caused by organisms such as, but not limited to, P. aeruqinosa and S. aureus.
The peptides are also useful in the prevention or treatment of eye infections. Such infections may be caused by bacteria such as, but not limited to, P. aeruqinosa, S. aureus, and N. gonorrhoeae, by fungi such as but not limited to C. albicans and A. fumiqatus, by parasites such as but not limited to A.
castellani, or by viruses.
The peptides may also be effective in killing cysts, spores, or trophozoites of infection - causing organisms. Such organisms include, but are not limited to Acanthamoeba which forms
trophozoites or cysts, C. albicans, which forms spores, and A. fumiqatus, which forms spores as well.
The peptides may also be administered to plants in an effective antimicrobial or antiviral or antiparasitic amount to prevent or treat microbial or viral or parasitic contamination thereof.
In general, the peptide is employed to provide peptide dosages of from 0.1 mg. to 500 mg. per kilogram of host weight, when administered systemically. When administered topically, the peptide is used in a concentration of from .05% to 10%.
The peptides may be produced by known techniques and
obtained in substantially pure form. For example, the peptides may be synthesized on an automatic peptide synthesizer. Journal of the American Chemical Society, Vol. 85, pgs. 2149-54 (1963). It is also possible to produce such peptides by genetic
engineering techniques. In accordance with another embodiment, the peptides of the present invention may be employed in combination with a toxic ion for the purposes hereinabove described.
A toxic ion is one which when introduced into a target cell virus, or virally-infected call, inhibits and/or prevents and/or destroys the growth of the target cell, virus, or
virally-infected cell.
Such a toxic ion is one which in the absence of an ion channel forming peptide is unable to cross a natural or synthetic lipid membrane; in particular a cell membrane, in sufficient amounts to affect a cell adversely.
The peptide and toxic ion may be administered as a single composition or in separate compositions, and the single or separate compositions may include additional materials, actives and/or inactives, in addition to the peptide and toxic ion. As representative examples of toxic ions which may be employed, there may be mentioned fluoride, peroxide, bicarbonate, and silver ions.
The peptide and the toxic ion, whether administered or prepared in a single composition or in separate compositions, are employed in amounts effective to inhibit and/or prevent and/or destroy the growth of the target cell, virus, or virally-infected cell. In effect, the ion potentiates the action of the peptide, i.e., the amount of toxic ion is effective to reduce the minimum effective concentration of the peptide for inhibiting growth of a target cell, virus, or virally-infected cell.
The toxic ion, when used topically, is generally employed in a concentration of from 0.05% to 2.0%. When used systemically, the ion is generally employed in an amount of from 1 to 10 mg. per kg. of host weight. Peptide dosages may be within the ranges hereinabove described.
It is also to be understood that the peptide and toxic ion may be delivered or administered in different forms; for example, the toxic ion may be administered orally, while the peptide may be administered by IV or IP.
As representative examples of administering the peptide and toxic ion for topical or local administration, the peptide could be administered in an amount of up to about 1% weight to weight and the toxic ion delivered in an amount of about 50mM (about 0.1%). Alternatively, the toxic ion, in the form of a salt such as sodium fluoride, could be administered orally in conjunction with systemic administration of the peptide. For example, the peptide may be administered IV or IP to achieve a serum dose of 100 micrograms per milliliter (10 milligrams per kilogram) in conjunction with an oral dose of toxic ion, in particular, sodium fluoride, of 10 meq per kilogram.
In accordance with another embodiment, the peptides of the present invention may be administered to a host in combination with an antibiotic selected from the class consisting of
bacitracins, gramacidin, polymyxin, vancomycin, teichoplanin, aminoglycosides, hydrophobic antibiotics, penicillins,
monobactams, or derivatives or analogues thereof.
The bacitracins, gramacidin, polymyxin, vancomycin,
teichoplanin, and derivatives and analogues thereof, are a group of polypeptide antibiotics. A preferred bacitracin is bacitracin A.
Aminoglycosidβ antibiotics include tobramycin, kanamycin, amikacin, the gentamicins (e.g., gentamicin C1, gentamicin C2, gentamicin C1a), nβtilmicin, kanamycin, and derivatives and analogues thereof. The preferred aminoglycosides are tobramycin and the gentamicins. The aminoglycosides, and the bacitracins hereinabove described, tend to be hydrophilic and water-soluble.
Penicillins which may be employed include, but are not limited to benzyl penicillin, ampicillin, methicillin
(dimethoxyphenyl penicillin), ticaricillin, penicillin V
(phenoxymethyl penicillin), oxacillin, cloxacillin,
dicloxacillin, .flucloxacillin, amoxicillin, and amidinocillin. Preferred penicillins which may be employed are benzyl penicillin and ampicillin. A preferred monobactam which may be employed is aztreonam.
As representative examples of hydrophobic antibiotics which may be used in the present invention, there may be mentioned macrolides such as erythromycin, roxythromycin, clarithromycm, etc.; 9-N-alkyl derivatives of erythromycin; midecamycin acetate; azithromycin; flurithromycin; rifabutin; rokitamycin, a
6-O-methyl erythromycin A known as TE-031 (Taisho); rifapentine; benzypiperazinyl rifamycins such as CGP-7040, CGP-5909,
CGP-279353 (Ciba-Geigy); an erythromycin A derivative with a cyclic carbamate fused to the C11/C12 position of a macrolide ring known as A-62514 (Abbott); AC-7230 (Toyo Jozo);
benzoxazinorifamycin; difficidin; dirithromycin; a
3-N-piperdinomethylzaino methyl rifamycin SV known as FCE-22250 (Farmitalia); M-119-a (Kirin Brewery); a
6-O-methyl-1-4"-O-carbamoyl erythromycin known as A-63075
(Abbott); 3-formylrifamycin SV-hydrazones with diazabicycloalkyi side chains such as CGP-27557 and CGP-2986 (Ciba-Geigy); and 16-membered macrolides having a 3-O-alpha-L-cladinosyl moiety, such as 3-O-alpha-L-cladinosyldeepoxy rosaramicin; tylosins and acyl demycinosyl tylosins.
In addition to the macrolides hereinabove described, rifamycin, carbenicillin, and nafcillin may be employed as well.
Other antibiotics which may be used (whether or not
hydrophobic) are antibiotics which are 50-S ribosome inhibitors such as lincomycin; clindamycin; and chloramphenicol; etc.;
antibiotics which have a large lipid like lactone ring, such as mystatin; pimaricin, etc.
The peptide and antibiotic may be adminstered by direct administration to a target ceil or by systemic or topical administration to a host which includes the target cell, in order to prevent, destroy or inhibit the growth of a target cell.
Target cells whose growth may be prevented, inhibited, or destroyed by the administration of the peptides and antibiotic include Gram-positive and Gram-negative bacteria as well as fungal cells.
The antibiotic, such as those hereinabove described, or derivatives or analogues thereof, when used topically, is generally employed in a concetration of about 0.1% to about 10%. When used systemically, the antibiotic or derivative or analogue thereof is generally employed in an amount of from 1.25 mg. to about 45 mg. per kg. of host weight per day. Peptide dosages may be those as hereinabove described.
As representative exmples of administering the peptide and antibiotic for topical or local administration, the peptide could be admnistered in an amount of from about 0.1% to about 10% weight to weight, and the antibiotic is delivered in an amount of from about 0.1% to about 10% weight to weight.
In accordance with another embodiment, the peptides of the present invention may be administered in combination with an antiparasitic agent or an antifungal agent.
Antiparasitic agents which may be employed include, but are not limited to, anti-protozoan agents. Examples of specific anti-parasitic agents which may be employed include, but are not limited to, pentamidine isethionate, and propamidine isethionate (Brolene).
Anti-fungal agents which may be employed include, but are not limited to, ketoconazole. It is also to be understood that certain anti-parasitic agents may also have anti-fungal activity, and that certain anti-fungal agents may have anti-parasitic activity.
In accordance with another embodiment, the peptides of the present invention may be administered in combination with an antibiotic which inhibits DNA gyrase, which is an enzyme involved in the formation of bonds between individual coiling strands of replicating bacterial DNA. Thus, DNA gyrase is necessary for the normal replication- of bacterial DNA, and, therefore, antibiotics which inhibit DNA gyrase inhibit the normal replication of bacterial DNA.
Examples of antibiotics which inhibit DNA gyrase include nalidixic acid, oxolinic acid, cinoxacin, and quinolone
antibiotics which include ciprofloxacin, norfloxacin, ofloxacin, enoxacin, pefloxacin, lomefloxacin, fleroxacin, tosulfloxacin, temafloxacin, and rufloxacin.
In accordance with another embodiment, the peptides of the present invention may be administered for the purpose hereinabove described in combination with other biologically active
amphiphilic peptides, or in combination with ion channel-forming proteins.
Examples of biologically active amphiphilic peptides which may be employed in combination with the peptides of the present invention include magainin peptides, PGLa peptides, XPF peptides, CPF peptides, cecropins and sarcotoxins.
A magainin peptide is either a magainin such as magainin I, II, or III or an analogue or derivative thereof.
The magainin peptides generally include at least fourteen amino acids. A magainin peptide preferably has 22 or 23 amino acids.
As representative examples of such magainin peptides, there may be mentioned peptides having the following peptide sequences as listed in the accompanying sequence listing:
(a) (NH2) (SEQ ID. NO: 65) (OH) or (NH2)
(Magainin I)
(b) (NH2) (SEQ ID. NO: 66) (OH) or (NH2)
(Magainin II)
(c) (NH2) (SEQ ID. NO. 67) (OH) or (NH2)
(Magainin III)
The following are examples of peptide derivatives or analogues :
(d) (NH2 ) ( SEQ ID. NO : 68 ) (OH) or (NH2 )
( e ) (NH2 ) ( SEQ ID. NO: 69 ) (OH) or (NH2 ) ( f ) (NH2 ) ( SEQ ID . NO : 70 ) ( OH) or (NH2 )
Magainin peptides are described in Proc. Natl. Acad. Sci., Vol. 84, pgs. 5449-53 (Aug. 87). The term "magainin peptides" as used herein refers to the magainin peptides as well as
derivatives and analogues thereof including but not limited to the representative derivatives and analogues.
A PGLa peptide is either PGLa or an analogue or derivative thereof.
The PGLa peptides generally include at least seventeen amino acids and may include as many as forty amino acids.
An XPF peptide is either XPF or an analogue or derivative thereof. The XPF peptides generally include at least nineteen amino acids and may include up to forty amino acids.
As representative examples of PGLa and XPF peptides, there may be mentioned the following peptide sequences as well as appropriate analogues and derivatives thereof:
PGLa: (SEQ ID NO: 71) (NH2)
XPF: (SEQ ID NO: 72)
A review of XPF and PGLa can be found in Hoffman, et al., EMBO J., 2:711-714 (1983); Andreu, et al., J. Biochem,
149:531-535 (1985); Gibson, et al., J. Biol. Chem., 261:
5341-5349 (1986); and Giovannini, et al., Biochem J., 243:113-120 (1987).
A CPF peptide is either a CPF peptide or an analogue or derivative thereof. In general, a CPF peptide does not include more than 40 amino acids.
Representative examples of CPF peptides which may be
employed in combination with the peptides of the present
invention, some of which have been described in the literature, include the following sequences:
(I) (SEQ ID NO: 73)
(II) (SEQ ID NO: 74)
(III) (SEQ ID NO: 75)
(IV) (SEQ ID NO: 76) (V) (SEQ ID NO 77)
(VI) (SEQ ID NO 78)
(VII) (SEQ ID NO 79)
(VIII) (SEQ ID NO 80)
(IX) (SEQ ID NO 81)
(X) (SEQ ID NO 82)
(XI) (SEQ ID NO 83)
(XII) (SEQ ID NO 84)
(XIII) (SEQ ID NO 85)
The above is expressed as single letter code for amino acids.
A review of the CPF peptides can be found in Richter, K., Egger, R., and Kreil (1986) J. Biol. Chem. 261, 3676-3680;
Wakabayashi, T. Kato, H., and Tachibaba, S. (1985) Nucleic Acid'sResearch 13, 1817-1828; Gibson, B.W., Poulter, L., Williams, D.H., and Maggio, J.E. (1986) J. Biol. Chem. 261, 5341-5349.
The term cecropins includes the basic structure as well as analogues and derivatives thereof. The cecropins and analogues and derivatives thereof are described in Ann. Rev. Microbiol. 1987, Vol. 41, pages 103-26, in particular page 108, and in
Christensen, et al., PNAS Vol. 85, pgs. 5072-76, which are hereby incorporated by reference.
The term sarcotoxins includes the basic materials as well as analogues and derivatives thereof. The sarcotoxins and analogues and derivatives thereof are described in Molecular Entomology, pages 369-78, in particular page 375, Alan R. liss, Inc. (1987), which is hereby incorporated by reference.
Ion channel-forming proteins or peptides which may be employed in combination with the peptides of the present
invention include defensins, also known as human neutrophil antimicrobial peptides (HNP), major basic protein (MBP) of eosinophils, bactericidal permeability-increasing protein (BPI), and a pore-forming cytotoxin called variously perforin,
cytolysin, or pore-forming protein. Deferisins are described in Selsted, et al., J. Clin. Invest., Vol. 76, pgs. 1436-1439
(1985). MBP proteins are described in Wasmoen, et al., J. Biol. Chem., Vol. 263, pgs 12559-12563. (1988). BPI proteins are described in Ooi, et al, J. Biol. Chem., Vol. 262, pgs.
14891-14894 (1987). Perforin is described in Henkart, et al., J. Exp. Med., 160: 75 (1984), and in Podack, et al., J. Exp. Med., 160:695 (1984). The above articles are hereby incoroporated by reference.
The term ion channel-forming proteins includes the basic structures of the ion-forming proteins as well as analogues and derivatives.
The invention will now be further described with respect to the following examples; however, the scope of the present
invention is not to be limited thereby.
Example 1 - Antibacterial Assay
The procedure for the following antibacterial assay is based upon the guidelines of the National Committee for Clinical
Laboratory Standards, Document M7-T2, Volume 8, No. 8, 1988.
Stock solutions of the following Peptides (SEQ ID NO: 1) through (SEQ ID NO: 64) in accordance with the present invention are prepared at a concentration of 512 μg/ml in sterile deionized distilled water and stored at -70°C.
Peptide (1A) is of the same structural formula as Peptide (SEQ ID NO: 1), except that each amino acid residue is a D-amino acid residue.
The stock peptide solution is diluted in serial dilutions (1:2) down the wells of a microtiter plate so that the final concentrations of peptides in the wells are 0.25, 0.50, 1, 2, 4, 8, 16, 32, 64, 128, and 256 μg/ml. 1-5 X 105 CFUs/ml of either S. aureus ATCC 25923, E. coli ATCC 25922, or P. aeruqinosa ATCC 27853 were added to the wells in full strength Mueller Hinton broth (BBL 11443) from a mid-log culture. The inoculum is standarized spectrophotometrically at 600nm and is verified by colony counts. The plates are incubated for 16-20 hours at 37°C, and the minimal inhibitory concentration (MIC) for each peptide is determined. Minimal inhibitory concentration is defined as the lowest concentration of peptide which produces a clear well in the microtiter plate. The results are given in Table I below.
For purposes of explanation of Table I below, S is the MIC of the peptide against S. aureus, P is the MIC of the peptide against P. aeruqinosa, and E is the MIC of the peptide against
E.coli.
Example 2 - Antiparasitic Assay
Logarithmic phase axenic cultures of Acanthamoeba polyphaga trophozoites were grown at 30°C in fluid ppyg medium (2%
proteose-peptone; 0.5% yeast extract; 0.5% glucose; pH 7.2).
Cells were counted using a Coulter counter, and added to fresh ppyg medium to give a cell concentration of approximately 10,000 amoebas/ml. Cell suspensions were then transferred to Corning tissue culture flasks (25 cm3) to which either Peptide (SEQ ID
NO:1) or Peptide (SEQ ID NO: 43) had been added to appropriate concentrations, with each flask containing 10ml of medium. The flasks were incubated at 30°C. 0.5ml samples were removed from the flasks, generally over a 5-day period, for counting in a Coulter Counter.
For determination of Minimum Inhibitory Concentration (MIC) and Minimum Amoebicidal Concentration (MAC) of the trophozoites, the contents of appropriate flasks were centrifuged, washed free of "old" medium and peptide with dilute saline, resuspended in fresh ppyg medium, and transferred to Corning tissue culture tubes (16 X 125mm). The tubes were incubated at 30°C and examined at daily intervals for growth of amoebas. Minimum Amoebicidal Concentration is defined is the minimum concentration of peptide necessary to kill the trophozoites. The results are given in Table II below. TABLE II
Antiparasitic Activity Against Acanthamoeba polyphaqa
Trophozoites
Peptide MIC MAC
(SEQ ID NO:1) 20 25
(SEQ ID NO: 43) 25 40
The peptides of the present invention, whether administered alone or in combination with agents such as toxic ions,
antibotics, or other biologically active peptides or proteins as hereinabove described, may be employed in a wide variety of pharmaceutical compositions in combination with a non-toxic pharmaceutical carrier or vehicle such as a filler, non-toxic buffer, or physiological saline solution. Such pharmaceutical compositions may be used topically or systemically and may be in any suitable form such as a liquid, solid, semi-solid, injectable solution, tablet, ointment, lotion, paste, capsule or the like. The peptide and/or agent as hereinabove described may also be used in combination with adjuvants, protease inhibitors, or compatible drugs where such a combination is seen to be desirable or advantageous in controlling infection caused by harmful microorganisms including protozoa, viruses, parasites, fungi, and the like.
The peptide may be administerd to a host in particular an animal, in an effective antibiotic and/or anti-tumor and/or antiviral and/or antimicrobial and/or antispermicidal and/or antifungal and/or antiparasitic amount, or in an amount effective to stimulate wound healing in a host. The peptides may be administerd either alone or in combination with a toxic ion, antibiotic, or ion channel forming peptide or protein as
hereinabove described. When the peptide is administered in combination with a toxic ion, the activity of the peptide is potentiated. When the peptide is administered in combination with an agent as hereinabove described, it is possible to administer the peptide and agent in separate forms. For example, the agent may be administered systemically and the peptide may be administered topically.
When the peptide is adminitered topically, it may be administered in combination with a water-soluble vehicle, said water-soluble vehicle being in the form of an ointment, cream, lotion, paste or the like. Examples of water-soluble vehicles which may be employed include, but are not limited to, glycols, such as polyethylene glycol, hydroxycellulose, and KY Jelly. The water-soluble vehicle is preferably free of an oily substance.
The peptide may also be employed in combination with a toxic ion as hereinabove described in the form of an oral composition for oral hygiene. Such a composition may be incorporated into a wide variety of compositions and materials used for oral hygiene purposes, which include, but are not limited to, toothpastes, mouthwashes, tooth gels, and tooth powders. Such composition may thus be used to treat or prevent periodontal disease, to prevent or reduce plaque, and/or to prevent or treat or reduce dental caries. The peptide and toxic ion may be used to inhibit, prevent, or destroy the growth of Streptococcus mutans, which is associated with dental caries and periodontal disease.
Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, within the scope of the accompanying claims, the invention may be practiced other than as particularly described.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Berkowitz, Barry A.
Kari, U. Prasad
Maloy, W. Lee
(ii) TITLE OF INVENTION: Novel Peptide Compositions and Uses Therefore
(iii) NUMBER OF SEQUENCES: 85
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
Cecchi & Stewart
(B) STREET: 6 Becker Farm Road
(C) CITY: Roseland
(D) STATE: New Jersey
(E) COUNTRY: USA
(F) ZIP: 07068
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 3.5 inch diskette
(B) COMPUTER: IBM PS/2
(C) OPERATING SYSTEM: PC-DOS
(D) SOFTWARE: DW4.V2
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 07476629
(B) FILING DATE: 08-FEB-1990 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Olstein, Elliot M.
(B) REGISTRATION NUMBER: 24,025
(C) REFERENCE/DOCKET NUMBER: 421250-122
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 201-994-1700
(B) TELEFAX: 201-994-1744
(2) INFORMATION FOR SEQ ID N0:1
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Lys He Ala Gly Lys He Ala Lys He Ala
5 10
Gly Lys lle Ala Lys He Ala Gly Lys He
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 2
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide ( ix ) FEATURE :
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Lys lle Ala Lys lle Ala Gly Lys lle Ala
5 10
Lys lle Ala Gly Lys lle Ala Lys lle Ala
15 20
Gly
(2) INFORMATION FOR SEQ ID NO: 3
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
Lys lle Ala Gly Lys lle Gly Lys lle Ala
5 10
Gly Lys lle Gly Lys lle Ala Gly Lys lle
15 20
Gly
(2) INFORMATION FOR SEQ ID NO: 4
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide ( ix ) FEATURE :
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Lys Leu Ala Gly Lys Leu Ala Lys Leu Ala
5 10
Gly Lys Leu Ala Lys Leu Ala Gly Lys Leu
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 5
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Lys Phe Ala Gly Lys Phe Ala Lys Phe Ala
5 10
Gly Lys Phe Ala Lys Phe Ala Gly Lys Phe
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 6
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Lys Ala Leu Ser Lys Ala Leu Lys Ala Leu
5 10
Ser Lys Ala Leu Lys Ala Leu Ser Lys Ala
15 20
Leu
(2) INFORMATION FOR SEQ ID NO: 7
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
Lys Leu Leu Lys Ala Leu Gly Lys Leu Leu
5 10
Lys Ala Leu Gly Lys Leu Leu Lys Ala Leu
15 20
Gly
(2) INFORMATION FOR SEQ ID NO: 8
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
Lys Ala lle Gly Lys Ala lle Lys Ala lle
5 10
Gly Lys Ala lle Lys Ala lle Gly Lys Ala
15 20
lle
(2) INFORMATION FOR SEQ ID NO: 9
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
Gly lle Ala Lys lle Ala Lys Gly lle Ala
5 10
Lys lle Ala Lys Gly lle Ala Lys lle Ala
15 20
Lys
(2) INFORMATION FOR SEQ ID NO: 10
(i) SEQUENCE CHARACTERISTICS (A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Lys lle Ala Lys lle Phe Gly Lys lle Ala
5 10
Lys lle Phe Gly Lys lle Ala Lys lle Phe
15 20
Gly
(2) INFORMATION FOR SEQ ID NO: 11
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: Gly lle Ala Arg lle Ala Lys Gly lle Ala
5 10
Arg lle Ala Lys Gly lle Ala Arg lle Ala
15 20
Lys
(2) INFORMATION FOR SEQ ID NO: 12 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Lys Phe Ala Arg lle Ala Gly Lys Phe Ala
5 10
Arg lle Ala Gly Lys Phe Ala Arglle Ala
15 20
Gly
(2) INFORMATION FOR SEQ ID NO: 13
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 13: Gly Phe Ala Lyslle Ala Lys Gly Phe Ala
5 10
Lys Ile Ala Lys Gly Phe Ala Lyslle Ala
15 20
Lys (2) INFORMATION FOR SEQ ID NO: 14
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Lys lle Ala Gly Orn lle Ala Lys lie Ala
5 10
Gly Orn lle Ala Lys lle Ala Gly Orn lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 15
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
Lys lle Ala Arglle Ala Gly Lys lle Ala
5 10
Arg lle Ala Gly Lys lle Ala Arg lle Ala
5 20
Gly (2) INFORMATION FOR SEQ ID NO: 16
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: Orn lle Ala Gly Lys lle Ala Orn lle Ala
5 10
Gly Lys lle Ala Orn lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 17
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: Gly lle Ala Arg lle Phe Lys Gly lle Ala
5 10 Arg lle Phe Lys Gly lle Ala Arg lle Phe
15 20
Lys
(2) INFORMATION FOR SEQ ID NO: 18
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: Lys Nle Ala Gly Lys Nle Ala Lys Nle Ala
5 10
Gly Lys Nle Ala Lys Nle Ala Gly Lys Nle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 19
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: Lys Nle Ala Gly Lys lle Ala Lys Nle Ala
5 10
Gly Lys lle Ala Lys Nle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 20
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: Lys lle Ala Gly Lys Nle Ala Lys lle Ala
5 10
Gly Lys Nle Ala Lys lle Ala Gly Lys Nle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO:21
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: Lys Nva Ala Gly Lys Nva Ala Lys Nva Ala
5 10
Gly Lys Nva Ala Lys Nva Ala Gly Lys Nva
15 20
Ala
(2) INFORMATION FOR SEQ ID NO:22
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Lys Nva Ala Gly Lyslle Ala Lys Nva Ala
5 10
Gly Lyslle Ala Lys Nva Ala Gly Lys Nva
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 23
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) TTHER INFORMATION: amide-terminated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: Lys Leu Leu Ser Lys Leu Gly tys Leu Leu
5 10
Ser Lys Leu Gly Lys Leu Leu Ser Lys Leu
15 20
Gly
(2) INFORMATION FOR SEQ ID NO: 24
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
Lys Leu Leu Ser Lys Phe Gly Lys Leu Leu
5 10
Ser Lys Phe Gly Lys Leu Leu Ser Lys Phe
15 20
Gly
(2) INFORMATION FOR SEQ ID NO: 25
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE YYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: Lys lle Ala Gly Lys Nva Ala Lys lle Ala
5 10
Gly Lys Nva Ala Lys lle Ala Gly Lys Nva
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 26
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: His lle Ala Gly His lle Ala His lle Ala
5 10
Gly His lle Ala His lle Ala Gly His lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO:27
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amnno acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: Ala Gly Lys lle Ala Lys lle Ala Gly Lys
5 10
lle Ala Lys lle Ala Giy Lys lle Ala Lys
15 20
lle
(2) INFORMATION FOR SEQ ID NO: 28
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear.
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: lle Ala Lys lle Ala Gly Lys lle Ala Lys
5 10
lle Ala Gly Lys lle Ala Lys lle Ala Gly
15 20
Lys
(2) INFORMATION FOR SEQ ID NO: 29
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE YYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: Lys lle Ala Gly Arg lle Ala Lys lle Ala
5 10
Gly Arg lle Ala Lys lle Ala Gly Arg lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 30
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear.
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: Arg lle Ala Gly Arg lle Ala Arg lle Ala
5 10
Gly Arg lle Ala Arg lle Ala Gly Arg lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 31
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: Lys Val Ala Gly Lys lle Ala Lys Val Ala
5 10
Gly Lys lle Ala Lys Val Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 32
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE; amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: Lys lle Ala Gly Lys Val Ala Lys lle Ala
5 10
Gly Lys Val Ala Lys lle Ala Gly Lys Val
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 33
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: Ala Lys lle Ala Gly Lys lle Ala Lys lle
5 10
Ala Gly Lys lle Ala Lys lle Ala Gly Lys
15 20
lle
(2) INFORMATION FOR SEQ ID NO: 34
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Orn lle Ala Gly Orn lle Ala Orn lle Ala
5 10
Gly Orn lle Ala Orn lle Ala Gly Orn lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 35
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: Lys Phe Ala Gly Lyslle Ala Lys Phe Ala
5 10
Gly Lyslle Ala Lys Phe Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 36
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: Lyslle Ala Gly Lys Phe Ala Lyslle Ala
5 10
Gly Lys Phe Ala Lyslle Ala Gly Lys Phe
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 37
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide ( ix ) FEATURE :
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: Lys Cha Ala Gly Lys lle Ala Lys Cha Ala
5 10
Gly Lys lle Ala Lys Cha Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 38
(i) SEQUENCE CHARACTERISTICS
( A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: Lys Nle Ala Lys lle Ala Gly Lys Nle Ala
5 10
Lys lle Ala Gly Lys Nle Ala Lys lle Ala
15 20
Gly
(2) INFORMATION FOR SEQ ID NO: 39
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: Arg lle Ala Gly Lys lle Ala Arg lle Ala
5 10
Gly Lys lle Ala Arg lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 40
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: Har lle Ala Gly Har lle Ala Har lle Ala
5 10
Gly Har lle Ala Har lle Ala Gly Har lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 41
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: amide-terminated, Xaa is p-aminophenylalanine
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:
Xaa lle Ala Gly Lys lle Ala Xaa lle Ala
5 10
Gly Lys lle Ala .Xaa lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 42
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: amide-terminated, Xaa is p-aminophenylalanine
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:
Lys lle Ala Gly Xaa lle Ala Lys lle Ala
5 10
Gly Xaa lle Ala Lys lle Ala Gly Xaa lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 43
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: Lys Leu Ala Ser Lys Ala Gly Lys lle Ala Gly
5 10
Lys lle Ala Lys Val Ala Leu Lys Ala Leu
15 20
(2) INFORMATION FOR SEQ ID NO: 44
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: Lys lle Ala Gly Lys lle Ala Lys lle Ala Gly
5 10
Orn lle Ala Lys lle Ala Gly Lys lle Ala
15 20
(2) INFORMATION FOR SEQ ID NO: 45
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: Lys lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Arg lle Ala Lys lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 46
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: Lys lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Nle lle Ala Lys lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 47
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: .21 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: Lys lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Nva lle Ala Lys lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 48
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: Lys Phe Ala Gly Lys Phe Ala Lys Phe Ala Gly
5 10
Orn Phe Ala Lys Phe Ala Gly Lys Phe Ala
15 20
(2) INFORMATION FOR SEQ ID NO: 49
(i) SEQUENCE CHARACTERISTICS (A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: Lys, lle Ala Gly Lys Phe Ala Lys lle Ala
5 10
Gly Orn Phe Ala Lys lle Ala Gly Lys Phe
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 50
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: Lys lle Ala Gly Lys Nle Ala Lys lle Ala
5 10
Gly Orn Nle Ala Lys lle Ala Gly Lys Nle
15 20
Ala (2) INFORMATION FOR SEQ ID NO: 51:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-termianted
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:
Lys Met Ala Ser Lys Ala Gly Lys lle Ala
5 10
Gly Lyslle Ala Lys Val Ala Leu Lys Ala
15 20
Leu
(2) INFORMATION FOR SEQ ID NO: 52:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52
Lyslle Ala Ser Lys Ala Gly Lyslle Ala
5 10
Gly Lyslle Ala Lys Val Ala Leu Lys Ala Leu
15 20 (2) INFORMATION FOR SEQ ID NO: 53:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:
Lys lle Ala Ser Lys Ala Gly Lys Nle Ala
5 10
Gly Lys lle Ala Lys Val Ala Leu Lys Ala
15 20
Leu
(2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:
Lys Leu Ala Ser Lys Ala Gly Lys lle Ala
5 10 Gly Lyslle Ala Lys Val Ala Leu Lys Ala
15 20
Leu
(2) INFORMATION FOR SEQ ID NO: 55:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:
Lys Nle Ala Ser Lys Ala Gly Lys Nle Ala
5 10
Gly Lyslle Ala Lys Val Ala Leu Lys Ala Leu
15 20
(2) INFORMATION FOR SEQ ID NO: 56
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated, Xaa is p-aminophenylalanine.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: Lys lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Xaa lle Ala Lys lle Ala Gly Lys lle
15
Ala
(2) INFORMATION FOR SEQ ID NO: 57
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:
Lys lle Ala Gly Ala lle Ala Lys lle Ala
5 10
Gly Lys lle Ala Lys lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 58
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amid--terminated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:
Lys lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Ala lle Ala Lys lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 59
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
( ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:
Lys lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Lys lle Ala Lys lle Ala Gly Ala lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 60
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:
Lys lle Ala Lys Lys lle Ala Lys lle Ala
5 10
Lys Lys lle Ala Lys lle Ala Lys Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 61
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:
Ala lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Lyslle Ala Lys lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 62
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TEPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:
Lys lle Ala Gly Lys lle Ala Ala lle Ala
5 10
Gly Lys lle Ala Lys lle Ala Gly Lys lle
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 63
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:
Lys lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Lys lle Ala Ala lle Ala Gly Lys He
15 20
Ala
(2) INFORMATION FOR SEQ ID NO: 64
(i) QEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (D) OTHER INFORMATION: amide-terminated
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:
Gly Met Ala Ser Lys Ala Gly Lys lle Ala
5 10
Gly Lys lle Ala Lys Val Ala Leu Lys Ala
15 20
Leu
(2) INFORMATION FOR SEQ ID NO: 65
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 23 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: Magainin I peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Zasloff, Michael
(C) JOURNAL: Proceedings of the National Academy
of Sciences
(D) VOLUME: 84
(F) PAGES: 5449-5453
(G) DATE: AUG - 1987
(H) DOCUMENT NUMBER: US 4810777
(I) FILING DATE: 04-MAR-1987
(J) PUBLICATION DATE: 07-MAR-1989 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65
Gly lle Gly Lys Phe Leu His Ser Ala Gly
5 10
Lys Phe Gly Lys Ala Phe Val Gly Glu lle
15 20
Met Lys Ser
(2) INFORMATION FOR SEQ ID NO: 66
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 23 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: Magainin II peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Zasloff, Michael
(C) JOURNAL: Proceedings of the National Academy
of Sciences
(D) VOLUME: 84
(F) PAGES: 5449-5453
(G) DATE: AUG - 1987
(H) DOCUMENT NUMBER: US 4810777
(I) FILING DATE: 04-MAR-1987
(J) PUBLICATION DATE: 07-MAR-1989
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66
Gly lle Gly Lys Phe Leu His Ser Ala Lys
5 10 Lys Phe Gly Lys Ala Phe Val Gly Glu lle
15 20
Met Asn Ser
(2) INFORMATION FOR SEQ ID NO: 67
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 22 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: Magainin III peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Zasloff, Michael
(C) JOURNAL: Proceedings of the National Academy
of Sciences
(D) VOLUME: 84
(F) PAGES: 5449-5453
(G) DATE: AUG - 1987
(H) DOCUMENT NUMBER: US 4810777
(I) FILING DATE: 04-MAR-1987
(J) PUBLICATION DATE: 07-MAR-1989
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:
Gly lle Gly Lys Phe Leu His Ser Ala Lye
5 10
Lys Phe Gly Lys Ala Phe Val Gly Glu lle
15 20
Met Asn (2) INFORMATION FOR SEQ ID NO: 68
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 22 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: magainin peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Zasloff, Michael
(C) JOURNAL: Proceedings of the National Academy
of Sciences
(D) VOLUME: 84
(F) PAGES: 5449-5453
(G) DATE: AUG - 1987
(H) DOCUMENT NUMBER: US 4810777
(I) FILING DATE: 04-MAR-1987
(J) PUBLICATION DATE: 07-MAR-1989
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:
lle Gly Lys Phe Leu His Ser Ala Lys Lys
5 10
Phe Gly Lys Ala Phe Val Gly Glu lle Met
15 20
Asn Ser
(2) INFORMATION FOR SEQ ID NO: 69
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: magainin peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Zasloff, Michael
(C) JOURNAL: Proceedings of the National Academy
of Sciences
(D) VOLUME: 84
(F) PAGES: 5449-5453
(G) DATE: AUG - 1987
(H) DOCUMENT NUMBER: US 4810777
(I) FILING DATE: 04-MAR-1987
(J) PUBLICATION DATE: 07-MAR-1989
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:
Gly Lys Phe Leu His Ser Ala Lys Lys Phe
5 10
Gly Lys Ala Phe Val Gly Glu lle Met Asn
15 20
Ser
(2) INFORMATION FOR SEQ ID NO: 70
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: magainin peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Zasloff, Michael
(C) JOURNAL: Proceedings of the National Academy
of Sciences
(D) VOLUME: 84
(F) PAGES: 5449-5453
(G) DATE: AUG - 1987
(H) DOCUMENT NUMBER: US 4810777
(I) FILING DATE: 04-MAR-1987
(J) PUBLICATION DATE: 07-MAR-1989
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:
Lys Phe Leu His Ser Ala Lys Lys Phe Gly
5 10
Lys Ala Phe Val Gly Glu lle Met Asn Ser
15 20
(2) INFORMATION FOR SEQ ID NO: 71
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: PGLa peptide.
(D) OTHER INFORMATION: amide-terminated
()) PUBLICATION INFORMATION: (A) AUTHOR: Hoffman, et al.
(C) JOURNAL: EMBO J.
(D) VOLUME: 2
(F) PAGES: 711-714
(G) DATE: 1983
(A) AUTHOR: Andreu, et al.
(C) JOURNAL: Journal of Biochemistry
(D) VOLUME: 149
(F) PAGES: 531-535
(G) DATE: 1985
(A AUTHOR: Gibson, et al.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(A) AUTHOR: Giovannini, et al.
(C) JOURNAL: Biochem J.
(D) VOLUME: 243
(F) PAGES: 113-120
(G) DATE: 1987
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: Gly Met Ala Ser Lys Ala Gly Ala lle Ala
5 10
Gly Lys lle Ala Lys Val Ala Leu Lys Ala
15 20
Leu
(2) INFORMATION FOR SEQ ID NO: 72
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: XPF peptide.
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Hoffman, et al.1
(C) JOURNAL: EMBO J.
(D) VOLUME: 2
(F) PAGES: 711-714
(G) DATE: 1983
(A) AUTHOR: Andreu, et al.
(C) JOURNAL: Journal of Biochemistry
(D) VOLUME: 149
(F) PAGES: 531-535
(G) DATE: 1985
(A) AUTHOR: Gibson, et al.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(A) AUTHOR: Giovannini, et al.
(C) JOURNAL: Biochem J.
(D) VOLUME: 243
(F) PAGES: 113-120
(G) DATE: 1987
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: Gly Trp Ala Ser Lys lle Gly Gin Thr Leu
5 10
Gly Lys lle Ala L s Val Gly Leu Lys Glu
15 20
Leu lle Gin Pro Lys
25 (2) INFORMATION FOR SEQ ID NO: 73
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES: 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349 (G) DATE : 1986
(H) DOCUMENT NUMBER: W090/04407
(I) FILING DATE: 16-OCT-1989
(J) PUBLICATION DATE: 03-MAY-1990
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:
Gly Phe Gly Ser Phe Leu Gly Leu Ala Leu
5 10
Lys Ala Ala Leu Lys lle Gly Ala Asn Ala
15 20
Leu Gly Gly Ala Pro Gin Gin
25
(2) INFORMATION FOR SEQ ID NO: 74
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T. Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES : 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol, Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(H) DOCUMENT NUMBER:. W090/04407
(I) FILING DATE: 16-OCT-1989
(J) PUBLICATION DATE: 03-MAY-1990
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74 Gly Leu Ala Ser Phe Leu Gly Lys Ala Leu
5 10
Lys Ala Gly Leu Lys lle Gly Ala His Leu
15 20
Leu Gly Gly Ala Pro Gin Gin
25
(2) INFORMATION FOR SEQ ID NO: 75
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide ( ix ) FEATURE :
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME : 261
(F) PAGES : 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES : 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(H) DOCUMENT NUMBER: W090/04407
(I) FILING DATE: 16-OCT-1989
( J ) PUBLICATION DATE: 03-MAY-1990
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:
Gly Leu Ala Ser Leu Leu Gly Lys Ala Leu
5 10 Lys Ala Gly Leu Lys lle Gly Thr His Phe
15 20
Leu Gly Gly Ala Pro Gin Gin
25
(2) INFORMATION FOR SEQ ID NO: 76
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES: 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L. Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(H) DOCUMENT NUMBER: W090/04407
(I) FILING DATE: 16-OCT-1989
(J) PUBLICATION DATE: 03-MAY-1990
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:
Gly Leu Ala Ser Leu Leu Gly Lys Ala Leu
5 10
Lys Ala Thr Leu Lys lle Gly Thr His Phe
15 20
Leu Gly Gly Ala Pro Gin Gin
25
(2) INFORMATION FOR SEQ ID NO: 77
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil (C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES : 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES : 1817-1828
(0) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES : 5341-5349
(G) DATE: 1986
(H) DOCUMENT NUMBER: W090/04407
(I) FILING : DATE: 16-OCT-1989
(J) PUBLICATION DATE: 03-MAY-1990
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77 Gly Phe Ala Ser Phe Leu Gly Lys Ala Leu
5 10
Lys Ala Ala Leu Lys lle Gly Ala Asn Met
15 20
Leu Gly Gly Thr Pro Gin Gin
25
(2) INFORMATION FOR SEQ ID NO: 78
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids (B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES : 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES : 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES : 5341-5349
(G) DATE: 1986
(H) DOCUMENT NUMBER: W090/04407
(I) FILING DATE: 16-OCT-1989 (J) PUBLICATION DATE: 03-MAY-1990
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:
Gly Phe Gly Ser Phe Leu Gly Lys Ala Leu
5 10
Lys Ala Ala Leu Lys lle Gly Ala Asn Ala
15 20
Leu Gly Gly Ala Pro Gin Gin
25
(2) INFORMATION. FOR SEQ ID NO: 79
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER- INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13 (F) PAGES: 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(H) DOCUMENT NUMBER: W090/04407
(I) FILING DATE: 16-OCT-1989
(J) PUBLICATION DATE: 03-MAY-1990
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:
Gly Phe Gly Ser Phe Leu Gly Lys Ala Leu
5 10
Lys Ala Ala Leu Lys lle Gly Ala Asn Ala
15 20
Leu Gly Gly Ser Pro Gin Gin
25
(2) INFORMATION FOR SEQ ID NO: 80
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated (x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES: 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(H) DOCUMENT NUMBER: W090/04407 (I) FILING DATE: 16-OCT-1989
( J ) PUBLICATION DATE: 03-MAY-1990
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80: Gly Phe Ala Ser Phe Leu Gly Lys Ala Leu
5 10
Lys Ala Ala Leu Lys lle Gly Ala Asn Leu
15 20
Leu Gly Gly Thr Pro Gin Gin
25 (2) INFORMATION FOR SEQ ID NO: 81
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES: 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349 (G) DATE: 1986
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:
Gly Phe Ala Ser Phe Leu Gly Lys Ala Leu
5 10
Lys Ala Ala Leu Lys lle Gly Ala Asn Ala
15 20
Leu Gly Gly Ala Pro Gin Gin
25
(2) INFORMATION FOR SEQ ID NO: 82
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES: 1817-1828 (G) DATE : 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:
Gly Phe Ala Ser Phe Leu Gly Lys Ala Leu
5 10
Lys Ala Ala Leu Lys lle Gly Ala Asn Met
15 20
Leu Gly Gly Ala Pro Gin Gin
25
(2) INFORMATION FOR SEQ ID NO: 83
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil (C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES: 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83: Gly Phe Gly Ser Phe Leu Gly Lys Ala Leu
5 10
Lys Ala Ala Leu Lyslle Gly Ala Asn Ala
15 20
Leu Gly Gly Ser Leu Gin Gin
25
(2) INFORMATION FOR SEQ ID NO: 84
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 -amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K.
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676,-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL; Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES: 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 5341-5349
(G) DATE: 1986
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:
Gly Phe Gly Ser Phe Leu Gly Lys Ala Leu
5 10
Lys Ala Gly Leu Lys lle Gly Thr Asn Phe
15 20
Leu Gly Gly Ala Pro Gin Gin
25 (2) INFORMATION FOR SEQ ID NO: 85
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: CPF peptide.
(D) OTHER INFORMATION: amide- or carboxy- terminated
(x) PUBLICATION INFORMATION:
(A) AUTHOR: Richter, K
Egger, R.
Kreil
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES: 3676-3680
(G) DATE: 1986
(A) AUTHOR: Wakabayashi, T.
Kato, H.
Tachibaba, S.
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES: 1817-1828
(G) DATE: 1985
(A) AUTHOR: Gibson, B.W.
Poulter, L.
Williams, D.H.
Maggio, J.E.
(C) JOURNAL: J. Biol. Chem.
(D) VOLUME: 261
(F) PAGES : 5341-5349 (G) DATE: 1986
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85 Gly Leu Ala Ser Leu Leu Gly Lys Ala Leu
5 10
Lys Ala Ala Leu Lys lle Gly Ala Asn Ala
15 20
Leu Gly Gly Ser Pro Gin Gin
25

Claims

WHAT IS CLAIMED IS:
1. A biologically active amphiphilic peptide, said peptide including one of the following basic structures X 1 through X7, wherein
X1 is -[R1-R2-R2-R3-R1-R2-R2]-n;
X2 is -[R2-R2-R3-R1-R2-R2-R1]-n;
X3 is -[R2-R3-R1-R2-R2-R1-R2]-n;
X4 is -[R3-R1-R2-R2-R1-R2-R2]-n;
x5 is -[R1-R2-R2-R1-R2-R2-R3]-n;
X6 is -[R2-R2-R1-R2-R2-R3-R1]-n; and
X7 is -[R2-R1-R2-R2-R3-R1-R2]-n;
wherein R1 is a basic hydrophilic amino acid, R2 is a hydrophobic amino acid, R3 is a neutral hydrophilic or hydrophobic amino acid, and n is from 2 to 5.
2. The peptide of Claim 1 wherein n is 3.
3. The peptide of Claim 2 wherein said peptide has the following structural formula:
(Lys lle Ala Gly Lys lle Ala)3-NH2
4. The peptide of Claim 2 wherein said peptide has the following structural formula:
(Lys lle Ala Lys lle Ala Gly)3-NH2
5. A composition comprising the peptide of Claim 1, and a pharmaceutical carrier.
6. The composition of Claim 5 wherein said peptide is present in an amount effective to inhibit growth of a target cell.
7. A process for inhibiting growth of a target cell, virus, or virally-infected cell, comprising:
administering a biologically active amphiphilic
peptide, said peptide including one of the following basic structures X1 through X7, wherein:
X1 is -[R1-R2-R2-R3-R1-R2-R2]-n,
X2 is -[R2-R2-R3-R1-R2-R2-R1]-n;
X3 is -[R2-R3-R1-R2-R2-R1-R2]-n; X4 is - [ R3 -R1-R2-R2-R1-R2-R2 ] -n;
X5 is -[R1-R2-R2-R1-R2-R2-R3]-n;
X6 is - [ R2 -R2-R1-R2-R2 -R3-R1 ] -n; and
X7 is -[R2-R1-R2-R2-R3-R1-R2]-n;
wherein R1 is a basic hydrophilic amino acid, R2 is a hydrophobic amino acid, R3 is a neutral hydrophilic, basic hydrophilic, or hydrophobic amino acid, and n is from 2 to 5.
8. The process of Claim 7 wherein n is 3.
9. The process of Claim 8 wherein said peptide has the following structural formula:
(Lys lle Ala Gly Lys lle Ala)3-NH2.
10. The process of Claim 8 wherein said peptide has the following structural formulae
(Lys lle Ala Lys lle Ala Gly)3-NH2.
11. The process of Claim 7 wherein said administering is to an animal host in an effective anti-tumor amount.
12. The process of Claim 7 wherein said administering is to an animal host in an effective anti-viral amount.
13. The process of Claim 7 wherein said administering is to an animal host in an effective antimicrobial amount.
14. The process of Claim 7 wherein said administering is to an animal host in an effective anti-parasitic amount.
15. The process of Claim 7 wherein said administering is to an animal host in an effective antibiotic amount.
16. The process of Claim 7 wherein said administering is to an animal host in an effective anti-spermicidal amount.
17. The process of Claim 7 wherein said administering is to an animal host in an amount effective in treating healing of a wound in said animal host.
18. A biologically active amphiphilic peptide, said peptide including the following basic structure: X14:
R1-R2-R2-R3-R4-R2-R2-R1-R2-R2-R2-R4-R2-R2, wherein R1 is a basic hydrophilic amino acid, R2 is a hydrophobic amino acid, R3 is a neutral hydrophilic or a hydrophobic amino acid, and R4 is a basic hydrophilic or hydrophobic amino acid.
19. The peptide of Claim 26 wherein the peptide includes the following structure:
Y14-X14, wherein X14 is the basic peptide structure of Claim 18, and Y14 is:
(i) R2;
(ii) R2-R2;
(iii) R4-R2-R2;
(iv) R3-R4-R2-R2;
(v) R2-R3-R4-R2-R2;
(vi) R2-R2-R3-R4-R2-R2; or
(vii) R1-R2-R2-R3-R4-R2-R2.
20. The peptide of Claim 18 wherein the peptide includes the following structure:
X14-Z14, wherein X14 is the basic peptide structure of Claim 18 and Z14 is:
(i) R1;
(ii) R1-R2;
(iii) R1-R2-R2;
(iv) R1-R2-R2-R3;
(v) R1-R2-R2-R3-R4;
i (vi) R1-R2-R2-R3-R4-R2; or
(vii) R1-R2-R2-R3-R4-R2-R2.
21. The peptide of Claim 18 wherein the peptide includes the following basic structure:
(Y14)a-(X14)-(Z14)b, wherein Y14 and Z14 are as previuosly described in Claims 19 and 20, a is 0 or 1 and b is 0 or 1.
22. The peptide of Claim 21 wherein said peptide has the following structural formula:
Lys Leu Ala Ser Lys Ala Gly Lys lle Ala Gly Lys
5 10
lle Ala Lys Val Ala Leu Lys Ala Leu - NH2 15 20
23. The peptide of Claim 21 wherein said peptide has the following structural formula:
Lys lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Orn lle Ala Lys lle Ala Gly Lys lle
15 20
Ala - NH2
24. A composition comprising the peptide of Claim 18 and a pharmaceutical carrier.
25. The composition of Claim 24 wherein said peptide is present in an amount effective to inhibit growth of a target cell.
26. A process for inhibiting growth of a target cell, virus, or virally-infected cell, comprising:
administering a biologically active amphiphilic peptide, said peptide including the following basic structure X14:
R1-R2-R2-R3-R4-R2-R2-R,-R2-R2-R2-R4-R2-R2-, wherein R1 is a basic hydrophilic amino acid, R2 is a hydrophobic amino acid, R3 is a neutral hydrophilic or hydrophobic amino acid, and R4 is a basic hydrophilic or hydrophobic amino acid.
27. The process of Claim 26 wherein the peptide includes the following structure:
Y14-X14, wherein X14 is the basic peptide structure of Claim 29, and Y14 is:
(i) R2;
(ii) R2-R2;
(iii) R4-R2-R2;
(iv) R3-R4-R2-R2;
(v) R2-R3-R4-R2-R2;
(vi) R2-R2-R3-R4-R2-R2; or
(vii) R1-R2-R2-R3-R4-R2-R2.
28. The process of Claim 26 wherein the peptide includes the following structure: X14-Z14, wherein X14 is the basic peptide structure of Claim 29, and Z14 is:
(i) R1;
(ii) R1-R2;
(iii) R1-R2-R2;
(iv) R1-R2-R2-R3;
(V) R1-R2-R2-R3-R4;
(Vi) R1-R2-R2-R3-R4-R2; or
(Vii) R1-R2-R2-R3-R4-R2-R2.
29. The process of Claim 26 wherein the peptide includes the following basic structure:
(Y14)a-X14-(Z14)b, wherein Y14 and Z14 are as previously defined in Claims 27 and 28, and a is 0 or 1, and b is 0 or 1.
30. The process of Claim 29 wherein said peptide has the following structural formula
Lys Leu Ala Ser Lys Ala Gly Lys lle Ala Gly Lys
5 10
lle Ala Lys Val Ala Leu Lys Ala Leu - NH2
15 20
31. The peptide of Claim 29 wherein said peptide has the following structural formula:
Lys lle Ala Gly Lys lle Ala Lys lle Ala
5 10
Gly Orn lle Ala Lys lle Ala Gly Lys lle
15 20
Ala - NH2
32. The process of Claim 26 wherein said administering is to an animal host in an effective anti-tumor amount.
33. The process of Claim 26 wherein said administering is to an animal host in an effective anti-viral amount.
34. The process of Claim 26 wherein said administering is to an animal host in an effective anti-microbial amount.
35. The process of Claim 26 wherein said administering is to an animal host, in an effective anti-parasitic amount.
36. The process of Claim 26 wherein said administering is to an animal host in an effective antibiotic amount.
37. The process of Claim 26 wherein said administering is to an animal host in an effective anti-spermicidal amount.
38. The process of Claim 26 wherein said administering is to an animal host in an amount effective in treating a wound in said animal host.
39. The peptide of Claim 1 wherein each amino acid residue is a D-amino acid residue or glycine.
40. The peptide of Claim 18 wherein each amino acid residue is a D-amino acid residue or glycine.
41. A biologically active amphiphilic peptide including the following structural formula:
(Lys lle Ala Lys Lys lle Ala)n, wherein n is from 2 to 5.
42. The peptide of Claim 41 wherein said peptide has the following structural formula:
(Lys lle Ala Lys Lys lle Ala)3-NH2.
43. A process for inhibiting growth of a target cell, virus, or virally-infected cell, comprising:
administering to a host the biologically active amphiphilic peptide of Claim 41, said peptide being administered in an amount effective in inhibiting growth of a target cell, virus, or virally-infected cell in a host.
44. The process of Claim 43 wherein said administering is to an animal host is an effective anti-tumor amount.
45. The process of Claim 43 wherein said administering is to an animal host in an effective anti-viral amount.
46. The process of Claim 43 wherein said administering is to an animal host in an effective anti-microbial amount.
47. The process of Claim 43 wherein said administering is to an animal host in an effective anti-parasitic amount.
48. The process of Claim 43 wherein said administering is to an animal host in an effective antibiotic amount.
49. The process of Claim 43 wherein said administering is to an animal host in an effective anti-spermicidal amount.
50. The process of Claim 43 wherein said administering is to an animal host in an amount effective in treating or healing a wound in said animal host.
51. A biologically active amphiphilic peptide selected from the group consisting of:
(SEQ ID NO:61)-NH2
(SEQ ID NO:62)-NH2
(SEQ ID NO:63)-NH2; and
(SEQ ID NO:64)-NH2.
52. A process for inhibiting growth of a target cell, virus, or virally-infected cell, comprising:
administering a biologically active amphiphilic
peptide, said peptide selected from the group consisting of:
(SEQ ID NO:61)-NH2
(SEQ ID NO:62)-NH2
(SEQ ID NO:63)-NH2; and
(SEQ ID NO:64)-NH2.
EP19910904427 1990-02-08 1991-02-04 Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell Withdrawn EP0514464A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47662990A 1990-02-08 1990-02-08
US476629 1990-02-08

Publications (2)

Publication Number Publication Date
EP0514464A1 true EP0514464A1 (en) 1992-11-25
EP0514464A4 EP0514464A4 (en) 1993-04-28

Family

ID=23892624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910904427 Withdrawn EP0514464A4 (en) 1990-02-08 1991-02-04 Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell

Country Status (4)

Country Link
EP (1) EP0514464A4 (en)
JP (1) JPH07504152A (en)
CA (1) CA2035959A1 (en)
WO (1) WO1991012015A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017760A1 (en) * 1990-05-14 1991-11-28 Magainin Sciences Inc. Composition of and treatment with biologically active peptides having d-amino acid residues
EP0671930A4 (en) * 1991-07-25 1996-02-07 Magainin Pharma Prophylaxis and treatment of adverse oral conditions with biologically active peptides.
US6348445B1 (en) 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
AU674525B2 (en) * 1992-06-01 1997-01-02 Magainin Pharmaceuticals, Inc. Biologically active peptides having N-terminal substitutions
US5654274A (en) * 1992-06-01 1997-08-05 Magainin Pharmaceuticals, Inc. Biologically active peptides having N-terminal substitutions
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5455253A (en) * 1992-10-20 1995-10-03 Zeneca Limited Heterocyclic derivatives
US5424290A (en) * 1992-10-26 1995-06-13 Magainin Pharmaceuticals Inc. Biologically active peptides and uses therefor
AU693518B2 (en) * 1994-01-18 1998-07-02 Magainin Pharmaceuticals, Inc. Ion-channel forming amphiphilic peptides having n-terminal modifications
GB9504761D0 (en) * 1995-03-09 1995-04-26 Unilever Plc Amphiphilic peptide and analogs thereof
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
JP3860838B2 (en) 1995-08-23 2006-12-20 ユニバーシティー オブ ブリティッシュ コロンビア Antimicrobial cationic peptide and screening method thereof
DK2252627T3 (en) 2008-01-24 2017-08-14 Esperance Pharmaceuticals MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME.
KR101977846B1 (en) * 2008-12-19 2019-05-14 박스알타 인코퍼레이티드 Tfpi inhibitors and methods of use
CA2889475A1 (en) 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE436645C (en) * 1976-04-29 1996-07-04 Bonnierfoeretagen Ab Antigenically active polypeptide which can be used in cancer diagnosis and in the production of antibodies
US4659692A (en) * 1982-11-19 1987-04-21 The Regents Of The University Of California Cationic oligopeptides having microbicidal activity
DE3324534A1 (en) * 1983-07-07 1985-01-17 Ciba-Geigy Ag, Basel MODIFIED PROTEASE INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PRODUCTS PREPARED THEREOF
US4617149A (en) * 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
DE3438296A1 (en) * 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt NEW POLYPEPTIDES WITH A BLOOD-CLOTHING EFFECT, METHOD FOR THE PRODUCTION OR THEIR RECOVERY, THEIR USE AND THE CONTAINERS THEREOF
EP0209061B1 (en) * 1985-07-17 1994-01-12 Hoechst Aktiengesellschaft Peptides having an anticoagulant activity, process for their preparation, obtention, their use and agents containing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEBS LETTERS vol. 228, no. 2, February 1988, AMSTERDAM, HOLLAND pages 337 - 340 SORAVIA ET AL 'Antimicrobial properties of peptides from Xenopus granular gland secretions' *
See also references of WO9112015A1 *

Also Published As

Publication number Publication date
WO1991012015A1 (en) 1991-08-22
EP0514464A4 (en) 1993-04-28
CA2035959A1 (en) 1991-08-09
JPH07504152A (en) 1995-05-11

Similar Documents

Publication Publication Date Title
AU657781B2 (en) Novel biologically active peptide compositions and uses therefor
AU665030B2 (en) Biologically active amphiphilic peptide compositions and uses therefor
AU674525B2 (en) Biologically active peptides having N-terminal substitutions
US5424290A (en) Biologically active peptides and uses therefor
AU652261B2 (en) Novel biologically active peptide compositions and uses therefor
EP0514464A1 (en) Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell
AU654714B2 (en) Novel peptide compositions and uses therefor
EP0590044A1 (en) Composition and treatment with biologically active peptides having c-terminal substitutions
US5459237A (en) Peptide compositions and uses therefor
US5686563A (en) Biologically active peptides having n-terminal substitutions
AU693518B2 (en) Ion-channel forming amphiphilic peptides having n-terminal modifications

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920804

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950316

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MAGAININ PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970107